

1 **Title: Identification of a serum proteomic biomarker panel using**
2 **diagnosis specific ensemble learning and symptoms for early**
3 **pancreatic cancer detection**

4
5 **Authors:**

6 Alexander Ney^{1,*}, Nuno R. Nené^{2,3,4*}, Eva Sedlak², Pilar Acedo¹, Oleg Blyuss^{2,5,6},
7 Harry J. Whitwell^{2,7,8}, Eithne Costello⁹, Aleksandra Gentry-Maharaj^{2,10}, Norman R.
8 Williams¹¹, Usha Menon¹⁰, Giuseppe K. Fusai¹², Alexey Zaikin^{2,13,14}, Stephen P.
9 Pereira^{1,*}.

10
11 **Affiliations:**

12
13 ¹ Institute for Liver and Digestive Health, University College London, Upper 3rd Floor,
14 Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

15
16 ² Department of Women's Cancer, EGA Institute for Women's Health, University
17 College London, 84-86 Chenies Mews, London, WC1E 6HU, United Kingdom

18
19 ³ Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD,
20 United Kingdom.

21
22 ⁴ Department of Statistical Science, University College London
23 1-19 Torrington Place, London, WC1E 6BT, United Kingdom

24
25 ⁵ Wolfson Institute of Population Health, Queen Mary University of London,
26 Charterhouse Square, EC1M 6BQ, London, United Kingdom

27
28 ⁶ Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's
29 Health, Sechenov First Moscow State Medical University (Sechenov University),
30 Moscow, Russia

31 ⁷ National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of
32 Metabolism, Digestion and Reproduction, IRDB, Building Imperial College London,
33 W12 ONN, United Kingdom

34 ⁸ Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of
35 Metabolism, Digestion and Reproduction, Sir Alexander Fleming Building, Imperial
36 College London, SW7 2AZ, United Kingdom

37
38 ⁹ Department of Molecular and Clinical Cancer Medicine, University of
39 Liverpool, Liverpool, United Kingdom

40
41 ¹⁰ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology,
42 University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, United
43 Kingdom

45 ¹¹ Division of Surgery & Interventional Science, University College London, London,
46 United Kingdom

47

48 ¹² HPB & Liver Transplant Unit, Royal Free London, London NW3 2QG, United
49 Kingdom

50

51 ¹³ Institute for Cognitive Neuroscience, University Higher School of Economics,
52 Moscow, Russia

53

54 ¹⁴ Department of Mathematics, University College London, London WC1H 0AY, United
55 Kingdom

56

57 * These authors contributed equally to the work

58

59 To whom correspondence should be addressed:

60 Dr Alexander Ney (Email: alexander.ney.15@ucl.ac.uk)

61 Dr Nuno Rocha Nené (Email: nuno.nene.10@ucl.ac.uk)

62 Prof Stephen Pereira (Email: stephen.pereira@ucl.ac.uk)

63

64

65 **Abstract**

66

67 **BACKGROUND:** The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC)
68 are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of
69 symptoms with benign gastrointestinal conditions in early stage further complicates timely detection.
70 The suboptimal diagnostic performance of carbohydrate antigen (CA) 19-9 and elevation in benign
71 hyperbilirubinaemia undermine its reliability, leaving a notable absence of accurate diagnostic
72 biomarkers. Using a selected patient cohort with benign pancreatic and biliary tract conditions we aimed
73 to develop a biomarker signature capable of distinguishing patients with non-specific yet concerning
74 clinical presentations, from those with PDAC.

75

76 **METHODS:** 539 patient serum samples collected under the Accelerated Diagnosis of neuro Endocrine
77 and Pancreatic TumourS (ADEPTS) study (benign disease controls and PDACs) and the UK
78 Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, healthy controls) were screened using
79 the Olink Oncology II panel, supplemented with five in-house markers. 16 specialized base-learner

80 classifiers were stacked to select and enhance biomarker performances and robustness in blinded
81 samples. Each base-learner was constructed through cross-validation and recursive feature elimination
82 in a discovery set comprising approximately two thirds of the ADEPTS and UKCTOCS samples and
83 contrasted specific diagnosis with PDAC.

84

85 RESULTS: The signature which was developed using diagnosis-specific ensemble learning
86 demonstrated predictive capabilities outperforming CA19-9 and individual biomarkers in both discovery
87 and validation sets. An AUC of 0.98 (95% CI 0.98 – 0.99) and sensitivity of 0.99 (95% CI 0.98 - 1) at
88 90% specificity was achieved with the ensemble method, which was significantly larger than the AUC
89 of 0.79 (95% CI 0.66 - 0.91) and sensitivity 0.67 (95% CI 0.50 - 0.83), also at 90% specificity, for CA19-
90 9, in the discovery set ($p=0.0016$ and $p=0.00050$, respectively). During ensemble signature validation,
91 an AUC of 0.95 (95% CI 0.91 – 0.99), sensitivity 0.86 (95% CI 0.68 - 1), was attained compared to an
92 AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 – 0.56) at 90% specificity for CA19-9
93 alone ($p=0.0082$ and $p=0.024$, respectively). When validated only on the benign disease controls and
94 PDACs collected from ADEPTS, the diagnostic-specific signature achieved an AUC of 0.96 (95% CI
95 0.92 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95) at 90% specificity, which was still significantly higher
96 than the performance for CA19-9 taken as a single predictor, AUC of 0.79 (95% CI 0.64-0.93) and
97 sensitivity of 0.18 (95% CI 0.03 – 0.69) ($p=0.013$ and $p=0.0055$, respectively).

98 CONCLUSION: Our ensemble modelling technique outperformed CA19-9, individual biomarkers and
99 prevailing algorithms in distinguishing patients with non-specific but concerning symptoms from those
100 with PDAC, with implications for improving its early detection in individuals at risk.

101

102 Introduction

103

104 Pancreatic cancer (PC) remains lethal with approximately 500,000 new cases diagnosed globally each
105 year with a comparable number of deaths. Pancreatic ductal adenocarcinoma (PDAC) ranks as the
106 seventh primary cause of cancer-related mortality (1, 2). Projections suggest that by 2030, mortality
107 rates from PDAC will exceed that of other prevalent cancers, a shift which is attributed to an increasing
108 incidence of obesity, diabetes mellitus, alcohol consumption in some regions (Europe, North America,

109 and Oceania) and advancements in detection and institution of screening initiatives that facilitate the
110 timely identification of more common cancers (1-3). Across the European Union and the United
111 Kingdom, mortality rates of PDAC have surpassed lung, breast and prostate cancers, underscoring the
112 pressing need for enhancements in strategies for both detection and treatment of PC (4). These
113 improvements are crucial to mitigate the growing burden of this disease (5, 6).

114

115 The overall 5-year survival for PC patients is less than 10%. These figures improve in patients
116 diagnosed with pre-invasive lesions (intraepithelial neoplasia, mucinous cystic lesions) or small tumours
117 (< 2cm) detected at a localised stage (7). Patients with resectable disease are only identified in less
118 than 20% of cases and advances in early detection strategies hold potential for improving these dismal
119 figures (8, 9). The relatively low incidence and lifetime risk for PC in the general population (1.3%)
120 preclude asymptomatic, average-risk adult (>50 age) screening, and efforts are rather focused on high-
121 risk populations (9-11). Internationally, screening and surveillance is therefore recommended only in
122 high-risk individuals (genetically predisposed, family history and high-risk pancreatic cysts), where a
123 lifetime risk of at least 5% justifies their surveillance (9, 10, 12, 13). While surveillance in these high-
124 risk cohorts is consensus, we also reported on symptomatic cohorts in which the increased risk could
125 justify investigations, as an additional risk group (9, 14).

126

127 Existing evidence regarding the effect of timely diagnosis on outcomes in PDAC are limited, mostly due
128 to the lack of randomisation, appropriate statistical considerations and homogenisations of study
129 populations, and the topic remains an area of strong debate (15). Yet with research indicating that
130 PDAC progresses from early (T1) stage to advanced (T4) in just over a year, and larger pancreatic
131 cancers (>2 cm) metastases are detectable within approximately 3.5 months (range between 1.2 to 8.4
132 months), it is very likely that prompt identification of PC would improve its prognosis (15-17).

133

134 The reality of the situation however is that disease rarity, the presence of non-localising symptoms, the
135 relatively low positive predictive values even for cancer specific 'red-flag' and advanced symptoms (e.g.
136 weight loss, painless jaundice of 4-13%) challenge timely recognition in primary care settings, and a
137 substantial number of PC patients are diagnosed following prolonged periods of clinical uncertainty (18,
138 19). Previous case-control primary care studies associated various abdominal symptoms and increased

139 frequency of primary care consultations with PDAC, over the two years preceding its diagnosis (14, 20,
140 21). These data suggest another potential window of opportunity for acceleration of PC detection.

141

142 In roughly 30% of patients, PC manifests in the form of jaundice indicating tumour induced biliary
143 obstruction, which is more evident in pancreatic head tumours (22). Together with significant weight
144 loss, these frequently represent an already advanced disease. Although most often explained by benign
145 aetiologies, symptoms such as back or epigastric pain, dyspepsia, anorexia, bloating, changes in
146 consistency of stool, weight loss and anxiety/depression may also indicate an underlying pancreatic
147 malignancy (14, 20-23). Such symptoms in adults (age > 60 years) with lifestyle factors (including heavy
148 alcohol and tobacco consumption, obesity) and on the background of new or long-standing diabetes
149 and chronic pancreatitis, are worrisome (9, 14, 21). In such patients, the United Kingdom National
150 Institute for Health and Care Excellence (NICE) recommends direct access to cross-sectional imaging
151 by CT, FDG-PET/CT, or EUS within two weeks (24). Although shorter diagnostic intervals are
152 associated with extended survival, the non-specific clinical presentation and the complexity of
153 diagnostic pathways result in delayed referral to specialised centres (14).

154

155 To accelerate and improve cancer detection rates in the UK, 'electronic cancer decision support tools'
156 (eCDST) have been developed to support primary care clinicians in fast tracking investigations in cases
157 of suspected cancer (25-27). Risk prediction models/algorithms such as QCancer (25-27) combine
158 symptoms data, patient risk factors and laboratory tests to predict a risk of undiagnosed cancers of
159 various anatomical sites (colon, pancreas, renal, gastro-oesophageal and ovarian). These are digitally
160 available for primary care physicians through patient record and data management portals (such as
161 EMIS Web and INPS) and where higher risk justifies further investigations, could be combined with
162 blood biomarker panels for further risk stratification prior to more invasive workup.

163

164 When suspected, establishing a diagnosis will involve measurement of the serum marker CA19-9,
165 cross-sectional (computed tomography or magnetic resonance) imaging and histopathology
166 (endoscopic ultrasound guided tissue biopsy; EUS-FNB). CA19-9 is most reliable as a marker of tumour
167 resectability, prognosis and monitoring of disease progression (28, 29), but as a diagnostic marker it
168 performs poorly (median sensitivity and specificity of ~80%; AUC= 0.82), particularly in stage I/II disease

169 and in Lewis body negative patients (30, 31). The development of reliable and accurate diagnostic
170 biomarkers is essential for risk stratification and prioritisation of further investigations, as well as
171 justification of invasive interventions where the findings on imaging are unequivocal (32).

172
173 Using serum samples collected from a selected study cohort with benign pancreatic and biliary tract
174 conditions and applying robust machine learning stacked modelling, we therefore developed a serum
175 biomarker signature capable of differentiating PC patients from healthy individuals and patients with
176 benign abdominal conditions presenting with non-specific yet concerning symptoms for pancreatic
177 cancer, at higher rates than CA19-9 and other state-of-the-art biomarkers.

178
179

180 **Materials and Methods**

181
182

Study Design

183 As our cohort, we used serum samples from the Accelerated Diagnosis of neuro Endocrine and
184 Pancreatic TumourS (ADEPTS) study (33) (UCL/UCLH Research Ethics Committee reference
185 06/Q0512/106, IRAS Number 234637, NIHR portfolio no. 7343) study - an early detection study aimed
186 at detecting pancreatic cancer in patients at an earlier stage. As part of the Early Diagnosis Research
187 Alliance (EDRA), the ADEPTS study (previously referred to as TRANSLational research in BILiary tract
188 and pancreatic diseases (*TRANSBIL*) study), commenced in 2018 and included a multicentre
189 prospective blood sample collection from patients with non-specific but concerning symptoms
190 associated with PDAC. Patients were recruited at gastroenterology/hepatobiliary and surgical clinics at
191 University College London (UCLH) and the Royal Free Hospitals (RFH), London, UK. Blood samples
192 were collected from subjects with benign hepatobiliary conditions as well as those with PDAC (stages
193 I-IV). All patients recruited to the ADEPTS study provided written informed consent.

194 For PDAC patients, tumour staging was performed according to the AJCC 8th edition (TNM) based on
195 cross-sectional imaging and for those undergoing surgery, based on multi-disciplinary team recordings.
196 All included PDAC cases were histologically confirmed by UCLH and RFH local pathologists based on

197 tissue analysis obtained by endoscopic ultrasound guided fine needle biopsies or specimens obtained
198 during surgical resection.

199 For benign disease controls, patients were selected to include the following diagnoses: chronic
200 pancreatitis, intraductal papillary mucinous neoplasms (IPMN), or benign pancreatic diseases (e.g.,
201 serous cystadenomas and pancreatic heterotopia). Patients with acute and chronic pancreatitis,
202 pancreatic cysts, benign biliary duct diseases (e.g., IgG4 disease), liver disease, gastritis/reflux disease,
203 gallstones as well as those with familial history of pancreatic cancer, were also used. Samples also
204 included those collected from patients presenting with non-specific symptoms which were not otherwise
205 explained by an underlying gastrointestinal pathology (such as non-specific abdominal pain and irritable
206 bowel syndrome) as well as other malignancies. Medical history and confirmation of diagnosis was
207 obtained from hospital medical records and included GP and secondary clinic referral letters. For 45
208 patients, a QCancer score was available at time of specialist centre consultations. QCancer calculates
209 the probability of an individual as harbouring an existing, yet undiagnosed cancer, by considering their
210 specific risk factors and presenting symptoms. These are digitally available for primary care physicians
211 through patient record and data management portals such as EMIS Web and INPS and designed as
212 clinical decision support tools to aid in assessment of need for specialist referrals (34).

213

214 To further represent the healthy population we also used samples from 72 healthy control UKCTOCS
215 (35) samples that were collected from a nested case control discovery study part of UKCTOCS reported
216 before (36), which had been previously approved by the Joint UCL/UCLH Research Ethics Committee
217 A (Ref. 05/Q0505/57). Written informed consent for the use of samples in the UKCTOCS trial and
218 secondary ethically approved studies was obtained from donors and no data allowing identification of
219 patients was provided. The original UKCTOCS dataset from which data was used here was derived
220 from serum samples collected from post-menopausal women, aged between 50 and 74 years, who
221 were recruited between the years 2001 and 2005 (35). The collection of these samples was conducted
222 in accordance with a specific Standard Operating Procedure (SOP) (37, 38). For the current work our
223 interest lies only with the UKCTOCS matched non-cancer controls, i.e., with no cancer registry code,
224 from individual women selected based on collection date, age, and centre to minimize variation due to
225 handling and storage. Comprehensive information regarding diabetes status for the selected
226 UKCTOCS participants was either unavailable or incomplete. In addition, data on disease duration was

227 not accessible. Consequently, it was not feasible to stratify samples to discovery and validation sets
228 based on the type of diabetes they may have had. For the purposes of this study, only healthy controls
229 that were matched to PDAC cases, with less than one year to diagnosis, were utilized.

230

231 A total of 539 serum samples (493 controls and 46 PDAC cases, see Table 1) were analysed using the
232 Olink multiplex immunoassay Oncology II panel in addition to five in-house markers: Carbohydrate
233 antigen 19-9 (CA19-9), Interleukin 6 Cytokine Family Signal Transducer (IL6ST/IL6RB), von Willebrand
234 factor (VWF), Pyruvate kinase isozymes M1/M2 (PKM/PKM2) and Thrombospondin 2 (THBS2/TSP2).
235 The selection of additional markers, beyond CA19-9, was informed by our preceding research in early
236 detection of PDAC (36, 39). In those studies, a panel of markers was identified due to its demonstrated
237 ability to facilitate the early detection of pancreatic cancer, with a lead time of up to two years prior to
238 diagnosis.

239

240 **Serum analyte measurements**

241

242 All ADEPTS (33) samples were randomized for testing. Supplementary Table 1 summarizes dilution
243 factors and coefficients of variation. CA19-9 was measured using the Mucin PC/CA19-9 ELISA Kit
244 (Alpha Diagnostic International) according to the manufacturer, using a 1:4 serum dilution. For VWF,
245 we resorted to the Von Willebrand Factor Human ELISA Kit (abcam) at a 1:100 serum dilution.
246 IL6ST/IL6RB by Quantikine human soluble gp130 (R&D Systems), according to manufacturer
247 recommendations, at a 1:100 serum dilution. THBS2/TSP2 was measured using the Quantikine Human
248 Thrombospondin-2 Immunoassay (R&D Systems) at a 1:10 serum dilution. Pyruvate kinase M2 (PKM2)
249 was measured with an ELISA (Cloud-Clone Corp) at a 1:10 dilution.

250

251 We outsourced tests using the multiplex immunoassay Oncology II panel from Olink on all samples.
252 This Olink panel measured known cancer antigens, growth factors, receptors, angiogenic factors, and
253 adhesion regulators (as detailed in Supplementary Table 2). Identical assays were performed on a
254 subset of samples derived from the UKCTOCS study (37, 38).

255

256 To bridge the normalized protein expression values from Olink between the UKCTOCS and ADEPTS
257 datasets, we selected a representative sample set of 16 from each cohort and plated them together.

258 Subsequently, a correction was applied to the datasets using the statistical algorithms recommended
259 in the Olink data normalization white paper (40). This method ensured that the data from different
260 batches and studies were comparable, thereby enhancing the robustness and validity of the findings.

261

262 **Statistical analysis**

263

264 The selected set of ADEPTS samples used in this work was partitioned into two distinct sets: a discovery
265 subset, comprising two-thirds of the total sample size, and a validation subset, encompassing the
266 remaining one-third. Allocation into each set was performed by stratifying for specific age ranges,
267 diabetes status, PDAC status and control diagnosis class. For the PDAC cases, tumour stage was also
268 used. The age stratification ranges were the following: $18 < \text{Age} \leq 28$; $29 < \text{Age} \leq 38$; $39 < \text{Age} \leq 48$;
269 $49 < \text{Age} \leq 58$; $59 < \text{Age} \leq 68$; $69 < \text{Age} \leq 78$; $\text{Age} \geq 79$. The samples assigned to the control class were made
270 of benign conditions such as: Sphincter of Oddi dysfunction, Pancreatic Cyst, Other Cancer, Other
271 Biliary Duct Disease, No Relevant Diagnosis, Liver Disease, Irritable Bowel Syndrome, IgG4 Disease,
272 Gastritis/Reflux Disease, Gallstone Disease, Familial Pancreatic Cancer, Chronic Pancreatitis, Acute
273 Pancreatitis, Isolated LFT Derangement and Non-specific Abdominal Pain. We also added an additional
274 set of healthy control samples collected from a nested study done in UKCTOCS samples used in a
275 previous paper (41). The controls matched by age to the PDAC cases in the UKCTOCS cohort that had
276 a time to diagnosis below up to one year were selected. The allocation of these controls to the discovery
277 or validation sets was done according to the division used in our previous work (41). The number of
278 controls and cases collected for this study can be visualized in Figure 1. UKCTOCS controls are
279 identified as 'Healthy'. The discovery-validation split puts the prevalence of PDAC in the discovery set
280 at close to 8%. The prevalence of PDAC in the resulting validation was approximately 14%.

281

282 Receiver operating characteristic (ROC) curves were constructed for each model to assess diagnostic
283 performance. The area under the curve (AUC) for the ROC curves was used as the metric. Models and
284 techniques were compared based on their rank in the discovery under a 10-time repeated 5-fold cross-
285 validation resampling strategy. ROC curves were generated with the *pROC* R package (version 1.18.0,
286 <https://cran.r-project.org/web/packages/pROC/index.html>). 95% CI for AUCs were determined by
287 stratified bootstrapping. All AUC confidence intervals crossing 0.5 were considered to be non-

288 significant. P values comparing ROC curves were also calculated using the *pROC* package, under a
289 one-sided bootstrap approach with 10000 runs.

290

291 In order to evaluate the association between each of the single markers available for this work, including
292 clinical covariates (see Table 1 and Figure 1), and PDAC status, we used a logistic regression model
293 implemented in the *logistf* R package (<https://cran.r-project.org/web/packages/logistf/index.html>,
294 version 1.24.1). This approach fits a logistic regression model using Firth's bias reduction method. The
295 reported confidence intervals for odds ratios and tests were based on the profile penalized log likelihood
296 and incorporate the ability to perform tests where contingency tables are asymmetric or contain zeros.
297 The performance of single marker models was also verified in the discovery and validation sets (see
298 Supplementary Figure 1 and Supplementary Table 3 and 4). The same package was also used to verify
299 the association of the presence of symptoms and PDAC status (see Figure 4).

300

301 A comprehensive multi-dimensional examination of the collated data was conducted by employing two
302 distinct analytical frameworks. The first was a stacked ensemble algorithm where base-learners were
303 developed according to the same algorithm but in subsets of the discovery set where samples belonging
304 to a specific control diagnosis class were contrasted against the same 24 PDAC cases (see for example
305 the proportions in Figure 1). The resulting base-learners were then stacked by a logistic regression
306 model, (see Supplementary Table 5 for the resulting coefficients and Supplementary Figure 2 for the
307 stacking procedures). This approach aimed to leverage the predictive power of multiple models, thereby
308 enhancing the robustness and potentially leading to more precise predictive outcomes (36, 42, 43). For
309 each base-learner classifier we resorted to a Recursive Feature Elimination (RFE) routine with logistic
310 regression as the fitting algorithm available through *caret* (version 6.0-93, [https://cran.r-](https://cran.r-project.org/web/packages/caret/index.html)
311 [project.org/web/packages/caret/index.html](https://cran.r-project.org/web/packages/caret/index.html)) and oversampling of the minority class. This secures robust
312 selection of features when combined with cross validation and the selection process is encapsulated
313 inside an outer layer of resampling (44-46). Due to the prevalence of PDAC cases in the whole
314 dataset being low, random under sampling of the majority class, here benign and healthy controls,
315 would not have been sufficient to meet the demands of most algorithms. Therefore, creating an
316 ensemble of classifiers specialised in contrasting a specific diagnostic class against PDAC allowed
317 us to create more balanced subsets leading to increased performance (Figure 2). For the samples

318 collected from UKCTOCS no symptoms information was available and, therefore, we created a
319 separate classifier associated with this subset of individuals.

320

321 In addition to the stacked approach we also fitted state-of-the-art algorithms such regularized random
322 forests (RRF, version 1.9.4, <https://cran.r-project.org/web/packages/RRF/index.html>); extreme
323 gradient boosting trees (xgbTree, version 1.6.0.1, [https://cran.r-](https://cran.r-project.org/web/packages/xgboost/index.html)
324 [project.org/web/packages/xgboost/index.html](https://cran.r-project.org/web/packages/xgboost/index.html)); and a generalized linear model with RFE applied to
325 the whole discovery set (RFE glm, in *caret*). The latter allowed for testing if the division into diagnosis
326 specific classifier ensembles was advantageous at low but representative prevalence (Figure 2) in
327 a situation where we want to contrast PDAC cases with confounding diseases in a clinical setting.
328 All base-models were trained by 10 times repeated 5-fold cross-validation with over-sampling of the
329 minority class (see Table 1 and Supplementary Tables 6 and 7 for information on prevalence).

330

331 To verify if the PDAC index developed with the ensemble stacked approach had any association with
332 metrics used in the clinic but not taken into account in any stage of algorithm training, we also gathered
333 the QCancer score (47) for individuals in the ADEPTS study (see Figure 6).

334

335 The procedure for assessing feature importance in each base learner was a model-agnostic method
336 based on a simple feature importance ranking measure (48), implemented in the R package *vip* (version
337 0.3.2, <https://cran.r-project.org/web/packages/vip/index.html>). The model-agnostic interpretability, by
338 decoupling the interpretation from the model itself, introduces a level of flexibility that enables its
339 application across any supervised learning algorithm. Despite the algorithm used for each diagnosis-
340 specific classifier being the same, the model-agnostic approach allows us to be able to generalise the
341 computed importances to other work in the literature.

342

343 Enrichment analysis for each of the signatures developed was performed with the *gprofiler2* R package
344 (version 0.2.1, <https://cran.r-project.org/web/packages/gprofiler2/index.html>). A threshold for multiple
345 comparison correction under the framework of false discovery rate was instituted at 0.05.

346

347

348 **Results**

349 **Data set characteristics**

350 In the full set of samples collected from the ADEPTS cohort, age at the time of sample collection, 57.44
351 (range from 19.00 to 93.00) for controls and 69.72 (range from 43.00 to 91.00) for PDAC cases, emerged as a
352 risk factor (OR= 1.06 (95% CI 1.04 – 1.09), $p=2.47\times 10^{-7}$) (Table 1). As a predictor in a logistic regression
353 model age as a feature achieved a ROC AUC of 0.73 (95% CI 0.66-0.79), with a cut-off at 61.5 years
354 (calculated using the Youden J statistic). This finding was also observed in both the discovery
355 (Supplementary Table 6 and Figure 1, ROC AUC 0.74 (95% CI 0.64-0.83), cut-off at 70) and validation
356 sets (Supplementary Table 7 and Figure 1, 0.74 (95% CI 0.64-0.82), cut-off at 60), which incorporated
357 not only ADEPTS samples but also healthy control samples collected from UKCTOCS (35). In our past
358 research which was focused exclusively on UKCTOCS longitudinal samples, age similarly emerged as
359 a risk factor for PDAC (36). Furthermore, gender (OR=2.72 (95% CI 1.46 – 5.27), $p=0.0015$) and
360 ethnicity taken as a one-hot encoded variable (OR=2.02 (95% CI 1.34 – 3.03), $p=6.56\times 10^{-4}$) were also
361 confirmed as significantly associated with an increased risk of PDAC (Table 1). In the whole set of
362 samples collected from the ADEPTS cohort, men had a 2.72-fold risk of PDAC compared to their female
363 counterparts. Individuals of Caucasian ethnicity demonstrated a decreased risk of PDAC in a one
364 versus rest calculation (OR=0.38 (95% CI 0.20 – 0.69), $p=0.0018$) and no significant association was
365 found between PDAC risk and Asian or Afro-Caribbean ethnicity in the ADEPTS dataset under the
366 same modelling framework (Table 1). The association of gender and PDAC was also confirmed in the
367 discovery (OR=4.98 (95% CI 2.08 – 13.50), $p=0.00023$, Supplementary Table 6 and Figure 1) and
368 validation sets (OR=2.65 (95% CI 1.11 – 6.58), $p=0.028$ Supplementary Table 7 and Figure 1) , but
369 ethnicity, taken as a one-hot encoded variable, remained a significant predictor of PDAC only in the
370 validation set (OR=2.66 (95% CI 1.42 – 5.17), $p=0.0020$) (Supplementary Table 7 and Figure 1), which
371 as was highlighted above also includes healthy control UKCTOCS samples. Within the group of the
372 clinical covariates only age and gender are significant predictors of PDAC in both the discovery and
373 validation set (Figure 1), with only age achieving a significant AUC in the validation set between these
374 two. However, this was concomitant with remarkably low sensitivity (Sens), positive predictive (PPV)
375 value and negative predictive value (NPV) at 90% specificity (Spec): AUC 0.74 (95% CI 0.64-0.82),
376 Sens 0.13 (95% CI 0 - 0.39), PPV 0.16 (95% CI 0 - 0.36), NPV 0.88 (95% CI 0.86 – 0.91).

377 **Development of PDAC biomarker signature in the presence of confounding conditions**

378 To aid the early detection of this cancer in individuals at risk, we aimed to develop a biomarker signature
379 that could be used to differentiate between suspected PDACs and benign biliary conditions that often
380 overlap in clinical presentation. We applied a uniquely developed ensemble learning model, with a
381 logistic regression stacking layer (see Supplementary Figure 2 and statistical analysis in the Methods
382 section), to a set of 539 serum samples (493 controls and 46 PDAC cases) which were analysed using
383 the Olink Oncology II panel as well as four additional biomarkers we previously reported on (36). These
384 included IL6ST, VWF, THBS2 and CA19-9. The oncogenic and prognostic glycolytic enzyme PKM2
385 was additionally selected based on our past report of its diagnostic utility in biliary tract cancer patients
386 (49-51).

387 The application of stacked ensemble modelling as presented herein bolsters the robustness of
388 predictive outcomes, enhancing the performance of biomarker panels through the incorporation of
389 serum biomarker levels and relevant clinical covariates for distinct diagnostic classes. Each component
390 classifier within the ensemble is designed to provide a specialized distinction between confounding
391 diagnoses and PDAC, thereby establishing a heterogeneous set of classifiers that facilitates the precise
392 identification of PDAC (see statistical analysis section in Methods). Previous studies have attested to
393 the beneficial role of ensemble methods in augmenting early detection of PDAC against only healthy
394 controls (36). The implementation of stacked (Stack, Figure 2), specialized classifiers, developed within
395 the discovery set, generated a biomarker signature capable of predicting PDAC with an AUC of 0.98
396 (95% CI 0.98 – 0.99), sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV
397 0.99 (95% CI 0.97 - 1) at 90% specificity. In contrast, the predictive efficacy of CA19-9 in the discovery
398 set taken as a single predictor under a logistic regression model was 0.79 (95% CI 0.66 – 0.91)
399 ($p=0.0016$ under a one-sided bootstrap test comparing the two AUCs), sensitivity 0.67 (95% CI 0.50 -
400 0.83), PPV 0.32 (95% CI 0.26 - 0.38) and NPV of 0.97 (95% CI 0.96 - 0.99) at 90% specificity (see
401 Supplementary Table 3). Amongst all biomarkers, CA19-9 demonstrated the most significant
402 association (refer to Supplementary Table 3 and Supplementary Figure 1 for univariate trend
403 associations across the discovery set), and one of the highest performances in the validation set
404 (Supplementary Figure 1 and Supplementary Table 4).

405

406 In the validation set, the ensemble signature predicted PDAC with an AUC of 0.95 (95% CI 0.91 – 0.99),
407 sensitivity 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) at
408 90% specificity. Once again, this is an improvement with respect to CA19-9 ($p=0.0082$, one-sided
409 bootstrap test) taken as a univariate model developed in the discovery set; this CA19-9 model predicted
410 PDAC status with an AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 - 0.56), PPV
411 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98) at 90% specificity in the validation
412 set. If we further validate only on the benign disease controls and PDACs collected from ADEPTS, the
413 diagnostic-specific ensemble signature achieved an AUC of 0.96 (95% CI 0.92 – 0.99), sensitivity 0.82
414 (95% CI 0.64 – 0.95) at 90% specificity. This performance is also significantly higher than the
415 performance of CA19-9 in a univariate model: AUC of 0.79 (95% CI 0.64-0.93) ($p= 0.013$ when
416 compared with the full signature, one-sided test) and sensitivity of 0.18 (95% CI 0.03 – 0.69).

417 A closer examination of the individual performances of each base-learner classifier (Figure 2A and B)
418 reveals that the logistic regression stacked ensemble approach has superior performance in both
419 discovery and validation sets. Despite the best base-learner being trained on samples diagnosed as
420 'Gastritis/Reflux Disease' (Figure 2A and B), its performance was also superseded by the AUC
421 computed with the stack model, the logistic regression coefficients of which are delineated in
422 Supplementary Table 5. The stack model significantly relies on the "Healthy", "Chronic Pancreatitis",
423 "IgG4 Disease", "Irritable Bowel Syndrome", "Other Biliary Duct Disease", "Sphincter of Oddi
424 Dysfunction", "No Relevant Diagnosis", "Other Cancer" and "Pancreatic Cyst" base-learners. Even
425 though the remaining diagnostic class base-learners, including "Gastritis/Reflux Disease", did not reach
426 statistical significance ($p<0.05$), employing a stack that solely resorts to significant base-learners led to
427 a reduction in generalization capacity: AUC 0.98 (95% CI 0.97 – 0.99), sensitivity 0.98 (95% CI 0.95 –
428 1), PPV 0.92 (95% CI 0.91 – 0.92), NPV 0.97 (95% CI 0.94 – 0.99) in the discovery set; AUC 0.93 (95%
429 CI 0.87 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95), PPV 0.53 (95% CI 0.47 – 0.57), NPV 0.97 (95%
430 CI 0.95 – 0.99) in the validation set. Although the differences are not substantial, we retain the full set
431 of base-learners to enhance the generalization capacity for predicting PDAC in unseen data sets and
432 new samples.

433

434 The employment of stacked diagnosis-specialized classifiers surpassed the AUC performance of state-
435 of-the-art algorithms such as random forests (RRF) and extreme gradient boosting methods (xgbTree),
436 in terms of AUC, sensitivity, positive predictive value, and negative predictive value at 90% specificity
437 (Figure 2C and D); although the performance AUC of the stacked classifier was only marginally
438 significantly higher than that obtained with RRF ($p=0.040$, one-sided) and not significant when
439 compared with xgbTree ($p=0.26$, one-sided), the sensitivity values at 90% specificity obtained with the
440 alternative methods were, in fact, significantly lower, $p=0.028$ and $p=0.045$, respectively. The ensemble
441 also outperformed a logistic regression model with recursive feature elimination (Figure 2C and D) that
442 did not rely on ensemble modelling ($p=0.0066$, one-sided), further substantiating our choice of machine
443 learning paradigm for facilitating the identification of PDAC cases in a clinical setting where confounding
444 diagnoses may be present, and the prevalence is low.

445

446 The comprehensive index signature, incorporating all diagnostic categories, was constituted by 49
447 features, of which 44 were proteins (see Figure 3 for the importance associated with each). Among
448 these proteins, 21 demonstrated a significant association with PDAC in the discovery set; ICOSLG,
449 GPNMB, ESM-1, DLL1, VWF, ERBB2, FCRLB, CEACAM5, EGF, CTSV, FASLG, Creatinine, CPE,
450 CA9/CAIX, TBIL, CD207, CRP, CDKN1A, EPHA2, ITGAV, and MUC-16 (see Supplementary Figure 1
451 and Supplementary Tables 3). The remaining 23 proteins, namely CXCL13, ERBB3, FOLR1/FR-alpha,
452 FADD, ERBB4, CD27, AREG/AR, ADAM-TS-15, ABL1, ANXA1, CXCL17, CD70, CEACAM1, CD48,
453 IL6ST, CD160, PKM/PKM2, CYR61/CCN1, CRNN, ADAM-8, FOLR3/FRgamma, THBS2, GZMB, did
454 not demonstrate a significant association with PDAC in univariate models (see Supplementary Figure
455 1 and Supplementary Tables 3 and 4). Additionally, five clinical covariates—Gender, Age, Ethnicity,
456 Diabetes, and Body Mass Index (BMI)—were identified as important predictors following
457 comprehensive recursive feature elimination during cross-validation (Figure 3).

458 Gene Ontology (GO) and biological pathway enrichment (Kyoto Encyclopaedia of Genes and
459 Genomes; KEGG, Reactome Pathway Database; REAC and WikiPathways; WP) analysis was
460 performed for the selected set of features using g:Profiler (Supplementary Figure 3). Top significant
461 terms for biological processes (BP) included 'circulatory system development', 'blood vessel
462 morphogenesis', 'cell adhesion', 'angiogenesis', 'blood vessel development', 'regulation of cell
463 adhesion', 'positive regulation of cell population proliferation', 'cell-cell adhesion', and 'regulation of

464 developmental process'. Top relevant biological pathways included: 'PI3K-KAT signalling pathway',
465 'ERBB signalling pathway', 'pathways in cancer', 'proteoglycans in cancer', 'platinum drug resistance',
466 'prostate cancer', 'type I diabetes mellitus', 'MAPK signalling pathway' and 'focal adhesion'.

467

468 The scaled importance of each feature and diagnostic class/classifier is depicted in Figure 3. It is of
469 significance to note that not every biomarker was selected by each individualized classifier, highlighting
470 the requirement for an array of diverse predictors, each tailored to specific underlying conditions, to
471 effectively identify PDAC. This is consistent with the idea that heterogeneous ensembles are
472 fundamental for predictive capacity in blind datasets (36, 43).

473

474 Of the five selected clinical covariates, only Age, Ethnicity, and Gender manifested as significant
475 predictors of PDAC in the validation set, as illustrated in Figure 1 and explained in the data set
476 characteristics subsection (see also Supplementary Table 6 and 7). It is worth emphasizing that the
477 lack of significant association between certain markers and PDAC in the discovery set does not
478 preclude their inclusion in the signature. These variables were selected due to their contribution to the
479 enhanced robustness and generalization capacity in predicting PDAC during cross-validation with a
480 recursive feature elimination routine (see Methods). A similar trend was verified in prior work focussed
481 on ensemble models for PDAC early detection against healthy controls (36).

482

483 **Application of a reduced, 8-marker signature as a differentiator of PDAC from healthy and** 484 **benign controls**

485

486 Across all conditions, 8 features with relatively higher scaled importance that differentiated controls from
487 PDAC patients were selected (Figure 3). Importance is measured by the contribution of a specific
488 feature to the output of the model (see Methods), in our case the probability of PDAC. These included
489 CA19-9, VWF, CPE, CTSV, CEACAM1 and CD160 together with Diabetes and Age as
490 clinicodemographic variables. Diabetes was a predictor of the differences between PDAC against
491 familial cases, gastric reflux disease (GORD), sphincter of oddi (SOD) dysfunction, as well as healthy
492 controls.

493

494 CA19-9 levels were only selected as a top discriminating feature against PDACs in patients with
495 suspected sphincter of Oddi dysfunction, benign liver disease, irritable bowel syndrome (IBS), those
496 with isolated LFT derangements as well as distinguished healthy subjects and those with other cancers
497 (Figure 3 and Supplementary Table 8), from PDAC patients.

498

499 Von Willebrand Factor (VWF) levels differentiated PDAC from symptomatic patients with pancreatic
500 cysts, benign biliary duct diseases, non-abdominal conditions, patients with family history of PDAC,
501 those with GORD as well as healthy subjects.

502

503 The immunoglobulin like surface antigen molecule CD160 (peripheral natural killer cells and CD8⁺ T
504 lymphocytes) (52) and a proposed immune checkpoint inhibitor, was selected as a significant
505 differentiator of PDAC from benign biliary tract diseases (IgG4 disease), SOD dysfunction, IBS as well
506 as in familial pancreatic cancer subjects and other cancers. Cathepsin V (CTSV) levels were also a
507 predictor of multiple conditions against PDAC, including benign biliary diseases and in subjects
508 belonging to the familial PC cohort. In healthy subjects, however, this feature did not show significant
509 importance as a differentiator from PDAC.

510

511 Serum levels of the metallo-carboxypeptidase E (CPE) were a feature selected as significant in five
512 conditions (acute pancreatitis, gallstones and IgG4 disease, SOD dysfunction and GORD) as well as a
513 differentiator in those with FH of PC. A higher scaled importance was attributed to this enzyme against
514 CA19-9 when differentiating acute and chronic pancreatitis (CP), isolated LFT derangements,
515 unexplained abdominal pain and non-abdominal conditions versus PDAC (Figure 3).

516 THE CEA cell adhesion molecule (CEACAM1) was selected as a feature in patients with non-explained
517 recurrent abdominal pain, isolated LFT derangements, GORD, SOD dysfunction as well as a feature
518 selected against non-pancreatic cancers.

519 Chronic pancreatitis (CP) is a known risk factor for PDAC. In our index signature, the protein markers
520 selected against PDAC included ESM1, ICOSLG, CTSV, CXL17 (CXC motif chemokine ligand 17),
521 IL6ST, ITGAV, GZMB (granzyme B; secreted serine protease), with a reduced risk for cancer in
522 Caucasian ethnicity (53-55).

523

524

525 We therefore opted to assess their combined performance against CA19-9 as a single marker. Using a
526 similar stacking procedure as before, a reduced model was trained using the same ensemble approach
527 as that highlighted before but with only 8 features as the input. The reduced signature predicted PDAC
528 still with a high AUC value of 0.97 (95% CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95%
529 CI 0.91-0.92) and NPV of 0.98 (95% CI 0.94-1) at 90% specificity, in the discovery set (Supplementary
530 Figure 4C). In the validation set, however, the performance of the 8-marker signature was significantly
531 reduced ($p=0.00038$, one-sided) compared to the full stacked model (AUC of 0.84 (95% CI 0.75-0.94),
532 sensitivity 0.64 (95% CI 0.36-0.82), PPV 0.47 (95% CI 0.33-0.53) yet with a NPV of 0.95 (95% CI 0.91-
533 0.97) at 90% specificity (Supplementary Figure 4D)), and only marginally superior to CA19-9 as a single
534 marker ($p=0.18$, one-sided). On the other hand, the 8-marker signature still outperformed CA19-9 by a
535 relatively large margin when predicting PDAC against healthy UKCTOCS controls in the validation set:
536 AUC_{redsig} of 0.93 (95% CI 0.84 - 1), $sensitivity_{\text{redsig}}$ of 0.86 (95% CI 0.54 - 1), PPV_{redsig} 0.94 (95% CI 0.90
537 - 0.94), NPV_{redsig} 0.80 (95% CI 0.54 - 1); $AUC_{\text{CA19-9}}$ of 0.84 (95% CI 0.70 - 0.97), $sensitivity_{\text{CA19-9}}$ of
538 0.68 (95% CI 0.5 - 0.91), $PPV_{\text{CA19-9}}$ 0.92 (95% CI 0.89 - 0.94), $NPV_{\text{CA19-9}}$ 0.62 (95% CI 0.52 - 0.85),
539 at 90% specificity. Under a bootstrap test this AUC difference is significant $p=0.025$ (one-sided). In
540 addition, it also outperformed the full PDAC ensemble model when predicting PDAC against healthy
541 controls in the validation set, although the differences were not significant ($p=0.2$, one-sided): AUC_{sig} of
542 0.90 (95% CI 0.77 - 1), $sensitivity_{\text{sig}}$ of 0.86 (95% CI 0.54 - 1), PPV_{sig} 0.94 (95% CI 0.92 - 0.94), NPV_{sig}
543 0.80 (95% CI 0.66 - 1) at 90% specificity.

544

545 If on the other hand the reduced signature is validated in ADEPTS samples only, i.e. in PDACs plus
546 benign disease controls, the performance of the reduced signature is far inferior to the full signature:
547 AUC_{redsig} of 0.83 (95% CI 0.73 - 0.93) ($p=0.0009$ when compared with AUC_{sig} , one-sided test),
548 $sensitivity_{\text{redsig}}$ 0.59 (95% CI 0.27 - 0.82), PPV_{redsig} 0.47 (95% CI 0.29 - 0.55) and NPV_{redsig} 0.94 (95%
549 CI 0.89 - 0.97), at 90% specificity. This further justifies the use of the full ensemble signature in blind
550 data sets and in a scenario where there is limited information on a patient trajectory, despite its
551 increased complexity.

552 In consideration of the marker importance in the reduced model, no marker received a null significance
553 across all diagnostic specific base-learners, a divergence from observations in the comprehensive
554 signature. CA19-9 emerged with the largest average importance across conditions, which also
555 contrasted with the full model. Age and VWF were ranked with elevated average significance across
556 diverse conditions. It's pertinent to note that CPE levels manifested diminished scaled importance in
557 discerning healthy controls from PDAC, particularly when juxtaposed against CA19-9, age, and
558 CEACAM1 (refer to Supplementary Figure 5).

559

560 **Application of the full PDAC ensemble signature in symptomatic patients**

561 Our subsequent aim was to explore whether specific clinical manifestations were correlated with PDAC
562 status in our ADEPTS patient cohort, for which such information was available (refer to Supplementary
563 Figure 6 and Supplementary Table 9). As a similar type of data was not available for the UKCTOCS
564 subset (healthy controls) used in this work, we focussed this section on the ADEPTS cohort.

565

566 In our prior research, we analysed 12 "red-flag" symptoms reported by patients up to 22 months before
567 the diagnosis of pancreatic cancer was established (20). In this work, 'Vomiting' ($p=0.17$),
568 'Asymptomatic LFT Derangement' ($p=0.28$), 'Back pain' ($p=0.54$), 'Change in Bowel Habit' ($p=0.67$) and
569 'Rectal Bleeding' ($p=0.76$) were selected for PDAC (versus benign disease controls), yet only 'Jaundice'
570 ($p=3.22 \times 10^{-15}$), and 'Weight Loss' ($p=1.44 \times 10^{-6}$) were significantly associated with PC cancer cases in
571 the set of samples randomly selected from the ADEPTS cohort, in which the biomarker panel was tested
572 (Figure 4B and Supplementary Table 9). Unsurprisingly, 'Reflux' ($p=0.022$) and 'Bloating' ($p=0.048$)
573 were significantly associated with benign controls. Interestingly, 'Abdominal Pain', 'Heartburn',
574 'Anaemia', and 'Dysphagia' upon presentation were aligned more with the benign control cohort, albeit
575 not significantly (refer to Figure 4 and Supplementary Table 9).

576

577 Within the framework presented in preceding sections, our ensemble of classifiers was developed
578 independently of symptomatic data. To assess the overall efficacy of our signature and its predictive
579 capacity for PDAC, we scrutinized its performance on a subset of ADEPTS patients, belonging to both
580 discovery and validation cohorts, manifesting with 'Weight Loss' ($n=56$) and 'Jaundice' ($n=40$) (refer to

581 Figure 4 and Supplementary Table 9). For each sample within these cohorts, where symptom data was
582 accessible, probability scores were derived based on the ensemble model formulated using the whole
583 discovery set presented above. We should emphasize that no additional model refinement was
584 pursued. The decision to aggregate these probability scores is further rationalized by the relatively
585 limited patient count exhibiting 'Weight Loss' and 'Jaundice' within the individual discovery and
586 validation datasets (Supplementary Table 9). In the ADEPTS subset of samples presenting with 'Weight
587 Loss', an AUC of 0.95 (95% CI 0.90 - 0.1), a sensitivity of 0.94 (95% CI 0.29 - 1), a PPV of 0.80 (95%
588 CI 0.56 - 0.81), and a NPV of 0.97 (95% CI 0.74 - 1) at 90% specificity were achieved (Table 2 and
589 Figure 5). In patients presenting with 'Jaundice', an AUC of 0.89 (95% CI 0.79 - 0.99), a sensitivity of
590 0.73 (95% CI 0.36 - 0.91), a PPV of 0.90 (95% CI 0.82 - 0.92), and a NPV of 0.73 (95% CI 0.54 - 0.89),
591 at 90% specificity, were observed (Table 2 and Figure 5). Compared with the AUC obtained with a
592 simple CA19-9 logistic regression model developed in the discovery set and by concatenating the
593 probability scores in the discovery and validation as done above, a significantly lower AUC of 0.74 (95%
594 CI 0.58 - 0.90) is achieved ($p=1.29\times 10^{-11}$, one-sided bootstrap test), with a sensitivity of 0.53 (95% CI
595 0.24 - 0.76), a PPV of 0.70 (95% CI 0.50 - 0.77), and a NPV of 0.81 (95% CI 0.73 - 0.90), at 90%
596 specificity, for patients presenting with 'Weight Loss'. For patients presenting with 'Jaundice' an AUC of
597 0.70 (95% CI 0.53 - 0.86) is reached, also significantly inferior ($p= 1.94\times 10^{-7}$), with a sensitivity of 0.41
598 (95% CI 0.14 - 0.73), a PPV of 0.83 (95% CI 0.64 - 0.90), and a NPV of 0.55 (95% CI 0.46 - 0.73), at
599 90% specificity, for CA19-9 as the single predictor.

600

601 With respect to other non-localising symptoms of note (Figure 5, Table 2 and Supplementary Table 10),
602 the best predictive performance was noted for the full index signature where it was able to differentiate
603 patients presenting with 'abdominal pain' due to benign conditions vs. PDAC with an AUC of 0.98 (95%
604 CI 0.97-1), sensitivity of 0.94 (95% CI 0.81-1), PPV 0.43 (95% CI 0.40-0.45) and a NPV of 0.99 (95%
605 CI 0.98-1), at 90% specificity. In those presenting with 'change in bowel habit', an AUC of 0.97 (95% CI
606 0.92-1), sensitivity 0.86 (95% CI 0.81-1), PPV of 0.51 (95% CI 0.41-0.55) and NPV of 0.98 (95% CI
607 0.95-1) was obtained. Both the index and the 8-marker signature showed superior predictive
608 performance to CA19-9 as a single marker (see Supplementary Table 11 for the respective p-values).

609

610

611 **Correlation of the full PDAC ensemble signature with QCancer pancreatic score**

612

613 In our final analysis, we juxtaposed the performance of our full ensemble classifier PDAC index against
614 the QCancer risk prediction index, a clinical decision support tool available for primary care physicians,
615 that integrates a myriad of individual-specific risk factors including age, sex, ethnicity, clinical
616 measurements, diagnoses, and patient-reported symptoms into a risk stratifying point of care
617 questionnaire (47). The 'Today's QCancer' index evaluates an individual's current risk of having an
618 undiagnosed cancer as well as the specific risk for 9 distinct underlying cancer types, including
619 pancreatic ('pancreatic' score) (56, 57). The aim was to determine whether in combination, the QCancer
620 eCDST and our biomarker index signature would be able to better discriminate PDAC patients in a
621 symptomatic (ADEPTS) cohort or whether it would be redundant. As the current risk threshold set by
622 the NICE is at 3% for triggering specialist referrals (24), we opted to assess the combined performance
623 of our index signature and the eCDST at a same or lower cut-off values.

624

625 The number of samples for which a QCancer score was computed is illustrated in Figure 6C. Using the
626 diagnostic-specific ensemble model delineated previously, probability scores for samples in both
627 discovery and validation cohorts were used to ascertain the combined ROC AUC for those samples
628 possessing a QCancer score. This amalgamation was imperative, considering the reduced number of
629 samples with an associated QCancer score (Figure 6C). It should be emphasized that no subsequent
630 refinements or training of the algorithm were conducted. The ensemble stack index demonstrated a
631 remarkable performance, achieving an AUC of 0.98 (95% CI 0.97 – 0.99), a sensitivity of 0.99 (95% CI
632 0.97-1), a PPV of 0.91 (95% CI 0.90 – 0.91), and a NPV of 0.99 (95% CI 0.96 - 1), at 90% specificity.
633 Interestingly, when considering only samples with a QCancer risk above 2 or 2.5, the biomarker and
634 clinical covariate ensemble index exhibited comparatively lower performance (Figure 6A). For a
635 QCancer risk above 3.0, the performance of the index decreases minimally once again, which is
636 expected as the difficulty of correctly singling out cases from confounding controls is increased (Figure
637 6A). However, the QCancer pancreatic score did exhibit a correlation with the odds of PDAC as
638 determined by the ensemble classifier ($R=0.36$, $p=3.4 \times 10^{-8}$, Figure 6D) which highlights an important
639 link between the purely clinical variables recorded for this cohort and the PDAC signature. Most
640 importantly, the stacked index succeeded in attributing higher odds ratios above 1 to several PDAC
641 cases that would have otherwise escaped detection had a QCancer score above 3 been taken as the

642 risk predictor (Figure 6D). Contrarily, when depending exclusively on the QCancer score, and using it
643 to calculate the ROC AUC, the predictive capacity for PDAC in the ADEPTS samples is noticeably
644 diminished in comparison to the performance of the ensemble index (Figure 6B); this was verified in all
645 samples with a Qcancer score ($p=1.56\times 10^{-18}$, one-sided bootstrap test comparing AUCs), with a score
646 above 2 ($p=1.24\times 10^{-10}$), above 2.5 ($p=3.68\times 10^{-13}$) and above 3 ($p=2.33\times 10^{-8}$). This justifies the PDAC
647 signature as a useful complementary resource for enhanced and accelerated diagnosis in the clinic.

648

649 **Discussion**

650

651 Our objective was to construct a multi-biomarker signature that could effectively differentiate individuals
652 with non-specific yet concerning symptoms attributable to both benign abdominal pathologies and
653 PDAC. CA19-9 tumour marker blood levels are used clinically to help confirm PDAC diagnosis in a
654 clinical context (positive findings on imaging, histopathology), prognosticate and monitor recurrence
655 following tumour resections (58). Its absent expression in Lewis body negative blood group individuals,
656 an overall limited predictive capacity (79–81% test sensitivity and 82–90% specificity at best) and
657 especially in the presence of certain inflammatory pancreatobiliary conditions, have driven
658 researchers to rather combine it in multi-marker panels to enhance its predictive performance (29, 30,
659 58). In an evolving multi-omics area, reported panels have included proteins, circulating nucleic acids
660 (micro-RNA, cfDNA) or tumours cells, metabolites, and products of alternative DNA splicing and
661 methylations (58, 59), developed to differentiate PDAC from healthy and those with benign pathologies.
662 Yet, the role of such diagnostic and screening panels in symptomatic cohorts remains unestablished.

663

664 The sampled population in our study is an enriched, symptomatic, secondary care cohort where the
665 prevalence of PDAC was close to 8%, representing figures observed in our hepatobiliary specialised
666 referral centres. By using this target population and their unique set of serum samples provided by the
667 ADEPTS study (33), we were able to develop a biomarker signature in a cohort of patients who were
668 referred to our participating centres (University College London Hospitals, London UK and the Royal
669 Free Hospital, London UK) with various abdominal and hepatobiliary conditions which in symptomatic
670 presentation might overlap with PDAC (20). Moreover, we included samples from patients with known
671 risk factors for PC (chronic pancreatitis, those with family history of PDAC and cystic lesions of the

672 pancreas, CLPs) and with biliary conditions that are known confounders of CA19-9 (i.e. biliary tract
673 inflammation/obstruction, pancreatitis, CLPs) - the only tumour marker clinically applied in the workup
674 and management (29, 39, 60) of PDAC.

675

676 We employed ensemble methods, which have achieved impressive accuracy in numerous complex
677 classification tasks (36, 42, 43, 61). Specifically, we utilized stacking—a form of meta-learning (43)—to
678 create a superior-level predictive model based on the predictions of diagnostic-specific base classifiers.
679 These classifiers leveraged a diverse set of features, highlighting the fundamental importance of
680 heterogeneity arising from specific diagnoses when compared against PDAC, an approach previously
681 demonstrated to be effective (36, 42). Moreover, this study enabled us to evaluate the specificity of our
682 early detection machine learning approach (36) within a relevant symptomatic population, thereby
683 allowing us to address confounding factors that may impact their performance. The use of such
684 diagnostic specialized base-learners was further justified by the data asymmetry between PDAC cases
685 and controls observed in both the discovery and validation datasets.

686

687 Across all diagnosis classes (base learners) the index signature which comprised 44 clinical and serum
688 protein covariates predicted PDAC (all stages) with an AUC of 0.98 (95% CI 0.98 – 0.99); at 90%
689 specificity, a sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV 0.99 (95%
690 CI 0.97 - 1) was reached, in contrast to CA19-9 as a single predictor under a logistic regression model
691 - AUC 0.79 (95% CI 0.66 – 0.91), sensitivity 0.67 (95% CI 0.50 - 0.83), PPV 0.32 (95% CI 0.26 - 0.38)
692 and NPV of 0.97 (95% CI 0.96 - 0.99). On validation, an AUC of 0.95 (95% CI 0.91 – 0.99), sensitivity
693 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) was achieved
694 by the signature, compared to an AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 -
695 0.56), PPV 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98), for CA19-9.

696

697 The performance of this index panel must be appreciated within the context of the complex biology
698 associated with each of the ensembled diagnostic classes, i.e., the challenges associated with
699 biomarker alterations on the background of pancreatobiliary inflammatory and obstructive
700 pathologies. When applying a redacted, 8-marker signature (CA19-9, VWF, CPE, CTSV,
701 CEACAM1, CD160, Diabetes and Age) - features that were selected with relatively high importance

702 across most base learners, the performance was naturally reduced, yet still performed significantly
703 better against CA19-9 as a single marker during discovery. Using the general linear model stack as
704 was done in the case of the full index, the reduced signature predicted PDAC with AUC of 0.97 (95%
705 CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95% CI 0.91-0.92) and NPV of 0.98 (95% CI
706 0.94-1), at 90% specificity (Supplementary Figure 4C), values comparable to the full index. During
707 validation, however, the predictive capacity of the reduced signature was significantly reduced
708 compared to the full stacked model (Supplementary Figure 4D) and only marginally superior to CA19-
709 9 alone across the cohort. In contrast, it still outperformed CA19-9 by a significant margin when
710 predicting PDAC against healthy controls.

711
712 As validation of its performance, we also applied the full index signature to the cohort, which were re-
713 stratified based on presenting symptoms in contrast to the ensemble of classifiers which were
714 developed independently of symptomatic data and with no further model refinement. The aim was to
715 test the signature performance in differentiating PDAC cases from controls by accounting for presenting
716 symptoms, and which have been linked with repeated primary care consultations up to two-years prior
717 to PDAC diagnosis (20) (Figure 4). Enriched by fulfilling certain sociodemographic, clinical and
718 attributable suspicious symptom (identified using CDSTs such as QCancer tool), symptomatic patients
719 would form an ideal cohort for further risk stratification by minimally invasive blood biomarker testing for
720 prioritisation of more invasive (and costly) investigations. Yet, contrary to the full index, in the cohort
721 used in the current work the QCancer score used as the sole predictor of PDAC did not achieve
722 significant performances in samples above the threshold of 3%. This further motivates the recourse to
723 combined strategies where complementary biomarker panels such as those identified by ensemble
724 modelling approaches could improve early detection when used in conjunction with CDSTs.

725
726 In our test subjects, however, only 'Jaundice' ($p=3.22\times 10^{-15}$), and 'Weight Loss' ($p=1.44\times 10^{-6}$) were
727 significantly associated with PDAC. When testing the diagnostic performance of the full index signature
728 in all symptomatic patients presenting with 'Weight Loss', the signature significantly outperformed
729 CA19-9: $AUC_{signature}$ of 0.95 (95% CI 0.90 - 0.1) vs. AUC_{CA19-9} of 0.74 (95% CI 0.58 - 0.90) (Figure 5A,
730 Table 2 and Supplementary Table 11). 'Weight loss' has previously been reported to have the longest
731 diagnostic interval in a prospective primary cohort study (SYMPTOM pancreatic study), assessing

732 symptom trends and associated diagnostic intervals in PC (14). Attesting to the full index signature's
733 capacity as a rule out test in such patients, is its outstanding negative predictive value compared to that
734 of CA19-9 (0.97 95% CI 0.75-1 vs. 0.81 95% CI 0.73-0.9, respectively) (Table 2). Similarly, the index
735 signature performed superiorly to CA19-9 in jaundiced patients (AUC of 0.89 (95% CI 0.79 - 0.99) vs.
736 CA19-9 AUC of 0.70 (95% CI 0.53 - 0.86), see also Supplementary Table 11), which underscores once
737 again the increased capacity of the ensemble index to better identify PDAC in the presence of a known
738 confounder of CA19-9 (29, 39).

739
740 While our study provides valuable insights, it is not without limitations. While the observed prevalence
741 of PDAC in this study aligns with secondary care population trends, enhanced specificity and positive
742 predictive value would necessitate larger cohorts with an increased number of cases. Moreover, the
743 sample set representing the 'Healthy' control class warrants expansion to incorporate a more diverse
744 population of both men and women. This control class, derived from the UKCTOCS samples used in a
745 previous study (36), exclusively comprised women. Given its superior performance in predicting PDAC,
746 as depicted in Figure 2, the inclusion of male samples within this class could further enhance the breadth
747 of the panel of markers identified in this study. Lastly, although diabetes emerged both as a risk factor
748 and a central clinical covariate in our signature (including in the reduced panel), we must emphasize
749 and recognise the lack of complete (type, duration) data in the UKCTOCS cohort (36). Nevertheless,
750 diabetes mellitus (and in particularly of new onset) is an established risk factor and therefore its inclusion
751 as a relevant feature in the signature is of no surprise (9).

752
753 While both our index and reduced signature were superior to CA19-9 in their predictive performance
754 and compensated for asymmetric binary classes by creating a diagnostic-specific ensemble, its
755 complexity challenges its utilisation in clinic. Yet, in the current era of rapidly evolving assay
756 technologies, the utilization of a complex biomarker signature comprising numerous variables has
757 gained significant relevance. While the complexity of these biomarker signatures may pose analytical
758 challenges, the evolving assay technologies offer the means to effectively harness their potential.

759
760 Future enhancements however, will naturally necessitate the study of larger cohorts, potentially
761 incorporating a biomarker-contextualized machine learning perspective that accounts for sample-
762 specific aspects related to diagnosis, a strategy employed in other cancer research domains (62). The

763 utilization of disease trajectory tracking and clinical history analysis (63) may also facilitate the
764 application of advanced deep learning techniques and electronic health data. When combined with
765 ensemble biomarker signatures taken for example in a longitudinal context (36, 64), these approaches
766 could enhance the estimation of PDAC risk within an enriched symptomatic population.

767

768 **Data Availability:** Data requestors will need to sign a data access agreement and in keeping with
769 patient consent for secondary use obtain ethical approval for any new analyses.

770

771 **Acknowledgments:** We thank the participants of the ADEPTS study and UKCTOCS trial, the
772 management team, research nurses, interviewers, research assistants, and other staff who gathered
773 the data that was used in this work. This research was funded by Cancer Research UK (grant
774 C12077/A26223) and supported by the Pancreatic Cancer UK Early Diagnosis Award 2018, project
775 “The Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS (ADEPTS)” (IRAS Number:
776 234637, NIHR Portfolio no. 7343), and by the National Institute for Health Research (NIHR) University
777 College London Hospitals Biomedical Research Centre. UKCTOCS was core funded by the Medical
778 Research Council, Cancer Research UK, and the Department of Health with additional support from
779 the Eve Appeal, Special Trustees of Bart’s and the London, and Special Trustees of University College
780 London Hospitals. EC is supported by Cancer Research UK (C7690/A26881). UM acknowledges MRC
781 Core funding (MC_UU_00004/01). SPP is supported by Cancer Research UK Early Detection and
782 Diagnosis Programme EDDPGM-May22\100002 (CANDETECT, Co-PI Prof Fiona Walter).

783

784 **Author contributions:** AN, NRN, SPP, UM and AZ conceived the study. SPP, AZ and UM secured
785 funding. NRN constructed the models, performed the statistical analysis and produced the figures. AN
786 and NRN interpreted the data in collaboration with SPP and AZ. AN, NRN, SPP and AZ drafted the
787 paper. ES and AN performed the experiments for all in-house biomarkers. All authors contributed to
788 data acquisition and interpretation, and critically reviewed and approved the article:

789 AN, NRN, ES, PA, OB, HJW, EC, AGM, NRW, UM, GKF, AZ, SPP.

790

791 **Competing interests:** The authors declare the following competing interests: UM reports stock
792 ownership in Abcodia UK between 2011 and 2021; UM has received grants from the Medical Research

793 Council (MRC), Cancer Research UK, the National Institute for Health Research (NIHR), the India
794 Alliance, NIHR Biomedical Research Centre at University College London Hospital, and The Eve
795 Appeal; UM currently has research collaborations with iLOF, RNA Guardian and Micronoma, with
796 funding paid to UCL; UM holds patent number EP10178345.4 for Breast Cancer Diagnostics; AG
797 currently has research collaborations with Micronoma and iLoF, with the research funding awarded to
798 UCL. No other potential conflicts of interest were disclosed by any of the authors.

799

800

801

802

803

804

805

806

807

808

809

810

811

812

814 **Tables:**

815 **Table 1. Cohort characteristics.** The data set used to develop and test the classifiers is a combination of samples
 816 collected from ADEPTS cohort and selected controls from the UKCTOCS cohort. BMI: Body Mass Index. See
 817 Study Design in Materials and Methods section for additional details. Odds ratio (OR) and respective 95%
 818 confidence intervals are also provided in the p value column.
 819

Variable	Cases	Controls	p value
ADEPTS			
No. samples	46	421	
Stage I	4	-	-
Stage II	15	-	
Stage III	10	-	
Stage IV	16	-	
Unknown	1	-	
Mean age at sample draw (yr) (range)	69.72 (43.00-91.00)	57.44 (19.00-93.00)	2.47×10^{-7} OR= 1.06 (1.04 – 1.09)
Mean BMI (kg/m ²) (range)	24.84 (12.04-41.35)	25.30 (15.22-39.45)	0.47 OR=0.97 (0.88 – 1.06)
Gender			
Male	31	180	
Female	15	241	0.0015 OR=2.72 (1.46 – 5.27)
Diabetes			
Yes	10 (8 Type II, 1 Type I, 1 unspecified)	75 (34 Type II, 41 unspecified)	0.44 OR=1.34 (0.62 – 2.70)
No	36	346	
Ethnicity			
Caucasian	21	291	
Unknown	21	60	
Asian	3	30	6.56×10^{-4} OR=2.02 (1.34 – 3.03)
Other	2	18	
Afro/Caribbean	0	22	
UKCTOCS			
No. samples	-	72	-

Mean age at sample draw (yr) (range)	-	62.95 (50.44-76.86)	-
Mean BMI (kg/m2) (range)	-	26.53 (17.91-42.19)	-
Gender			
Male	-	-	-
Female	-	72	-
Diabetes			
Yes	-	3 (3 Type II)	-
No	-	69	-
Ethnicity			
Unknown	0	72	-

820
821
822

823 **Table 2 Performance summary for selected models in symptomatic patients.** The probability values used to
824 calculate the performance metrics were generated with each model developed in the training set and reported in
825 the main text. Probability values for symptomatic patients belonging to the training set and validation set were
826 concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.:
827 Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss.
828 95% confidence intervals are provided in parentheses. See also Supplementary Table 10 for the explicit
829 performance ranks according to model, symptom and metric and Figure 5.

830

Models	Metric	Symptom (Yes)				
		A.L.Derang.	A. Pain	A. B. Habit	W.Loss	Jaundice
CA19-9	ROC	0.85 (0.62-1)	0.81 (0.65-0.96)	0.82 (0.57-1)	0.74 (0.58-0.90)	0.70 (0.53-0.86)
	Sens90	0.75 (0.38-1)	0.69 (0.44-0.94)	0.71 (0.42-1)	0.53 (0.24-0.76)	0.41 (0.14-0.73)
	PPV90	0.54 (0.37-0.61)	0.36 (0.26-0.43)	0.46 (0.34-0.55)	0.70 (0.50-0.77)	0.83 (0.64-0.90)
	NPV90	0.96 (0.90-1)	0.97 (0.95-0.99)	0.96 (0.93-1)	0.81 (0.73-0.90)	0.55 (0.46-0.73)
Index signature	ROC	0.98 (0.95-1)	0.98 (0.97-1)	0.97 (0.92-1)	0.95 (0.90-1)	0.89 (0.79-0.99)
	Sens90	1 (0.62-1)	0.94 (0.81-1)	0.86 (0.56-1)	0.94 (0.29-1)	0.73 (0.36-0.91)
	PPV90	0.61 (0.49-0.61)	0.43 (0.40-0.45)	0.51 (0.41-0.55)	0.8 (0.56-0.81)	0.90 (0.82-0.92)
	NPV90	1 (0.94-1)	0.99 (0.98-1)	0.98 (0.95-1)	0.97 (0.75-1)	0.73 (0.54-0.89)
Reduced signature	ROC	0.97 (0.93-1)	0.92 (0.88-0.99)	0.91 (0.83-0.98)	0.92 (0.85-0.99)	0.82 (0.67-0.97)
	Sens90	1 (0.63-1)	0.81 (0.38-1)	0.57 (0.14-1)	0.71 (0.35-0.94)	0.77 (0-0.95)
	PPV90	0.61 (0.49-0.94)	0.40 (0.23-0.45)	0.41 (0.15-0.55)	0.75 (0.6-0.8)	0.90 (0-0.92)
	NPV90	1(0.94-1)	0.98 (0.95-1)	0.95 (0.9-1)	0.88 (0.76-0.97)	0.76 (0.42-0.94)


831

832

833 **Figures:**

834

835 **Figure 1 Characteristics of the discovery and validation sets.** Number of controls across the discovery and
836 validation sets **(A)**, number of PDAC cases per stage **(B)**, and association of BMI, Age, Diabetes, Ethnicity and
837 Gender with PDAC status **(C-F)**. In C, D, E and F dot sizes correspond to odds ratios and are colour coded
838 according to their respective values, i.e., blue if $OR < 1$ and red if $OR > 1$. p values were calculated according to a
839 logistic regression model with a bias reduction method. Purple dashed lines correspond to $-\text{Log}[0.05]$. **G** Receiver
840 Operating Curve (ROC) Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and
841 Negative Predictive Value (NPV) at 90% Specificity (Spec) performance of single marker models, i.e. BMI and Age,
842 in the validation set. **H** Similar to A but for Gender, Ethnicity and Diabetes. Performances were calculated with the
843 respective single feature models developed in the discovery set. The ROC AUC significance threshold is also
844 represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set are the 95%
845 Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See Statistical Analysis in Methods
846 (main text) for further details and Supplementary Table 6, 7 and 8.




847

848
849
850
851
852
853
854
855
856
857

858
859
860
861
862
863
864
865
866
867


Figure 2 Performance of individual base-learner classifiers, stack ensemble and state-of-the-art algorithms.
A Base-learners performance in the discovery set. Each base-learner classifier was developed by training with a recursive feature elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific diagnosis class against the same 24 PDACs in the discovery set. The performance reported in **A** is, nevertheless, of each classifier in the whole discovery set. The performances reported in **B** correspond to the base-learners developed in the discovery set but applied to the whole validation set. In **C** and **D** the performance of the ensemble stack based on the base-learners presented in **A** and **B**, as well as of state-of-the-art algorithms (xgbTree, RRF and RFE glm) is reported in the discovery and validation sets, respectively. xgbTree, RRF and RFE glm were trained in the whole discovery set, which contrasts with the ensemble algorithm.



868

870
871
872
873
874
875

Figure 3 Features selected per diagnosis class (base-learner classifiers). The scaled importance is calculated within each base-learner (Figure 2A). Selected features are ranked from left to right according to the average scaled importance across base learners. See Figure 1, Supplementary Figure 1 and Supplementary Tables 3 and 4 for the univariate predictive performances of each of the markers in the discovery and validation sets. See Methods section for details on model-agnostic algorithm for feature importance calculation.




876

877
878
879
880
881
882
883
884
885
886
887
888
889


890
891
892
893
894
895
896
897
898
899
900

Figure 4 Association between symptoms and PDAC. **A** Number of subjects with each symptom according to PDAC status, case or control. **B** Association of symptoms with PDAC status, p values were calculated according to a logistic regression model with a bias reduction method. Purple dashed lines correspond to $-\text{Log}[0.05]$. In **B** dot sizes correspond to odds ratios and are colour coded according to their respective values, i.e., blue if $\text{OR} < 1$ and red if $\text{OR} > 1$. See also Supplementary Table 9. Only samples belonging to the ADEPS cohort were used as no information about symptoms was available for the UKCTOCS set of samples.



901
902
903
904
905
906
907
908
909
910
911


Figure 5 Receiver operating curves for selected models in symptomatic patients. **A** Only CA19-9. **B** Full index signature. **C** Reduced index signature. The probability values used to calculate the performance metrics were generated with each model developed in the discovery set and reported in the main text. Probability values for symptomatic patients belonging to the discovery set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. See also Table 2 for numerical values for area under the curve and other metrics.



912
913

914
915
916
917
918
919
920
921
922
923
924

Figure 6 Prediction of PDAC in patients with specific symptoms and according to QCancer score values. The ensemble stack was selected as the best model according to Figure 2. **A** Performance of the stack in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. **B** Performance of the Qscore taken as the predictor of PDAC risk in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. **C** Number of subjects that had a calculated Qscore or are above a specific threshold, bigger than 2, 2.5 or 3.0. **D** Correlation between QCancer score and odds ratio of PDAC according to the stacked ensemble. E is in log scale. The QCancer score is identified as Qscore in the figure panels.



925
926

927 Supplementary Information

928 **Title: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble**
929 **learning and symptoms for early pancreatic cancer detection**

930 **Authors:**

931 Alexander Ney^{1,*}, Nuno R. Nené^{2,3,4*}, Eva Sedlak², Pilar Acedo¹, Oleg Blyuss^{2,5,6}, Harry J. Whitwell^{2,7,8},
932 Eithne Costello⁹, Aleksandra Gentry-Maharaj^{2,10}, Norman R. Williams¹¹, Usha Menon¹⁰, Giuseppe K.
933 Fusai¹², Alexey Zaikin^{2,13,14}, Stephen P. Pereira^{1,*}.

934

935 **Affiliations:**

936

937 ¹ Institute for Liver and Digestive Health, University College London, Upper 3rd Floor, Royal Free
938 Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

939

940 ² Department of Women's Cancer, EGA Institute for Women's Health, University College London, 84-
941 86 Chenies Mews, London, WC1E 6HU, United Kingdom

942

943 ³ Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD, United Kingdom.

944

945 ⁴ Department of Statistical Science, University College London
946 1-19 Torrington Place, London, WC1E 6BT, United Kingdom

947
948 ⁵ Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square,
949 EC1M 6BQ, London, United Kingdom

950
951 ⁶ Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's Health, Sechenov First
952 Moscow State Medical University (Sechenov University), Moscow, Russia

953 ⁷ National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism,
954 Digestion and Reproduction, IRDB, Building Imperial College London, W12 ONN, United Kingdom

955 ⁸ Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism,
956 Digestion and Reproduction, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ,
957 United Kingdom

958
959 ⁹ Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United
960 Kingdom

961
962 ¹⁰ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College
963 London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, United Kingdom

964
965 ¹¹ Division of Surgery & Interventional Science, University College London, London, United Kingdom

966
967 ¹² HPB & Liver Transplant Unit, Royal Free London, London NW3 2QG, United Kingdom

968
969 ¹³ Institute for Cognitive Neuroscience, University Higher School of Economics, Moscow, Russia

970
971 ¹⁴ Department of Mathematics, University College London, London WC1H 0AY, United Kingdom

972
973 * These authors contributed equally to the work
974

975 To whom correspondence should be addressed:

976 Dr Alexander Ney (Email: alexander.ney.15@ucl.ac.uk)

977 Dr Nuno Rocha Nené (Email: nuno.nene.10@ucl.ac.uk)

978 Prof Stephen Pereira (Email: stephen.pereira@ucl.ac.uk)

979

980

981

982

983

984

985 In this supplementary information we provide the additional tables and figures cited in the main text.

986

987

988

989

990 Supplementary Figures

991

992

993

994

995

996

997

998

999


1000

1001

1002

1003

Supplementary Figure 1 Biomarker ranks in the discovery set. **A** Distribution and ranks of biomarkers by p values in the discovery set. Purple dashed line corresponds to $-\text{Log}[0.05]$. **B** Receiver Operating Curve (ROC) Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) at 90% Specificity (Spec) performance of single marker models in the validation set. OR stands for odds-ratio, with dot size proportional to the calculated values. Red and blue OR points represent $\text{OR} > 1$ (favours pancreatic ductal adenocarcinoma (PDAC) case status) and $\text{OR} < 1$ (favours Control status), respectively. p values were calculated according to a logistic regression model with a bias reduction method. Performances were calculated with the single feature models developed in the discovery set. The ROC AUC significance threshold is also represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set correspond to 95% Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See statistical analysis section in Methods (main text) for further details and Supplementary Table 3 and 4.



1004

1005

1006

1007

1008

1009

1010

1011

1012

1013


1014

1015





1016

Supplementary Figure 2 Flow diagram for the stack ensemble classifier. The general linear stack model presented in the main text was built according to this diagram, where base-learners are trained in groups of control samples with a specific diagnosis and the same PDAC cases. The stacking procedure has 2 steps. First, the probability output vectors for each base-learner are concatenated, thus leading to n probability vectors, where n is the number of diagnosis subclasses. Second, these vectors are subsequently used to populate the diagonal blocks of a large probability matrix. The off-diagonal probability blocks are generated by using the base models trained in a specific diagnosis subclass plus the same PDACs, which therefore amounts to computing cross diagnosis predictions. The resulting large matrix has n columns and is then used to train the meta-learner which outputs the final probability vector. For the purposes of applying the resulting trained models to the validation set, the flow of the diagram is the same as before, but the feature matrix will have a different number of samples.

Diagnosis Ensemble Stack




1044 **Supplementary Figure 4 Performance of individual base-learner classifiers and stack ensemble for a**
1045 **reduced set of biomarkers, CA19-9, Age, Diabetes, VWF, CPE, CTSV, CEACAM1 and CD160. A** Base-learner
1046 performance in the discovery. Each base-learner classifier was developed by training with a recursive feature
1047 elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific diagnosis class
1048 against the same 24 PDACs in the discovery set. The performance reported in **A** is, nevertheless, of each classifier
1049 in the whole discovery set. The performances reported in **B** correspond to the base-learners developed in the
1050 discovery set but applied to the whole validation set. In **C** and **D** the performance of an ensemble GLM stack based
1051 on the base-learners presented in **A** and **B** is reported in the discovery and validation sets, respectively. The ROC
1052 AUC significance threshold is represented by a purple dashed line at 0.5. Error bars in figures correspond to 95%
1053 Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times.
1054
1055
1056




1057
1058
1059
1060
1061
1062
1063
1064
1065

1066 **Supplementary Figure 5 Feature importance for a reduced 8-marker model following the same principles**
1067 **as those described in Figure 2 A and B.** The reduced set of biomarkers was CA19-9, Age, Diabetes, VWF, CPE,
1068 CTSV, CEACAM1 and CD160. See also performances in Supplementary Figure 4. Selected features are ranked
1069 from left to right according to the average scaled importance across base learners. See Methods for details.
1070
1071



1073
 1074
 1075
 1076
 1077
 1078
 1079

Supplementary Figure 6 Matrix for associated symptoms for each sample. Each sample in the whole set collected from ADEPTS cohort is represented by the columns. The colour coding corresponds to the diagnosis class associated with each sample. Symptoms are represented in each row. Both columns and rows are clustered according to their symptoms pattern. Black represents presence of sample with the respective symptoms and diagnosis.



1080
 1081
 1082
 1083
 1084

1085

1086 **Supplementary Tables**

1087

1088 **Supplementary Table 1 Quantitative ELISA assays` intra-assay coefficient of variation.**

Assay	Dilution factor	CV(%)
CA19-9(A)	1:4	6.9
VWF	1:100	13.5
THBS2	1:10	12.5
PKM/PKM2	1:10	10.3
IL6ST/IL6RB	1:100	-

1089

1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098

Supplementary Table 2 Cancer-associated proteins measured on the Olink Oncology II panel used in this project. The remaining biomarkers were done in-house. The protein names are listed to be consistent with those provided by Olink.

PODXL	VEGF-A	VEGFR-2/KDR	VEGFR-3/LFT4	RSPO3	IL6	IFN-gamma-R1/IFNGR1
CXCL17	MK/MDK	MIC-A/B	WFDC2	ESM-1	MSLN	CEACAM1
ITGAV	GPC1	SYND1/SDC1	PVRL4/NECTIN4	TXLNA	Gal-1/GAL	LYPD3
IGF1R	LYN	ABL1	EPHA2	CDKN1A	PPY	SCF/KITLG
EGF	AREG/AR	ErbB2/HER2	ErbB3/HER3	ErbB4/HER4	WISP-1/CCN4	WIF-1
TRAIL/TNFSF10	TNFSF13	TNFRSF19	TNFRSF6B	TLR3	SMAD5/MAD5	FADD
KLK8/hK8	KLK11/hK11	KLK13	KLK14/hK14	CPE	XPNPEP2	CTSV
TFPI-2	SCAMP3	GZMB	GZMH	CYR61/CCN1	ADAM8	ADAM-TS 15
FCRLB	TCL1A	CD27	CD48	CD70	CD160	CD207
ANXA1	S100A4	S100A11	VIM	CRNN	DLL1	SEZ6L
FOLR3/FRgamma	5'-NT/NT5E	LY9	CA9/CAIX	FGF-BP1	ICOSLG	FOLR1/FR-alpha
MIA	CEACAM5/CEA	SPARC	HGF	TGFR-2/TGFRB2	FASLG/FasL	MetAP 2
CXCL13	ITGB5	RET	TGF-alpha/TGFA	TNFRSF4	GPNMB	FUR/FURIN
MUC16						

1099
 1100
 1101
 1102
 1103
 1104
 1105
 1106
 1107
 1108

1109

1110 **Supplementary Table 3 Odds ratios, p values, ROC AUC, sensitivity (Sens), positive predictive**
 1111 **value (PPV) and negative predictive value (NPV) for univariate logistic regression models**
 1112 **derived in the discovery set.** The performances of these model in the validation are presented in
 1113 **Supplementary Table 4. Markers are ranked according to the p values. Spec: specificity.**

1114

1115

Marker	OR	p value	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	1.85 (1.54 - 2.26)	1.87E-12	0.79 (0.66 - 0.91)	0.67 (0.5 - 0.83)	0.32 (0.26 - 0.38)	0.97 (0.96 - 0.99)
KITLG	0.23 (0.14 - 0.37)	7.95E-11	0.79 (0.68 - 0.89)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
CRP	2.01 (1.59 - 2.61)	4.12E-10	0.84 (0.74 - 0.92)	0.58 (0.38 - 0.83)	0.34 (0.25 - 0.42)	0.96 (0.94 - 0.98)
VWF	3.92 (2.28 - 7.78)	1.89E-09	0.84 (0.76 - 0.9)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
SDC1	4.42 (2.56 - 8.01)	8.47E-08	0.79 (0.66 - 0.89)	0.67 (0.46 - 0.83)	0.32 (0.25 - 0.38)	0.97 (0.96 - 0.99)
KDR	0.01 (0.00 - 0.07)	2.02E-07	0.8 (0.72 - 0.87)	0.42 (0.21 - 0.67)	0.23 (0.13 - 0.32)	0.96 (0.94 - 0.97)
TBIL	2.03 (1.55 - 2.75)	2.53E-07	0.72 (0.6 - 0.85)	0.54 (0.29 - 0.71)	0.32 (0.2 - 0.38)	0.96 (0.94 - 0.97)
TNFRSF6B	2.62 (1.80 - 3.94)	3.12E-07	0.75 (0.64 - 0.86)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
FASLG	0.20 (0.10 - 0.39)	2.39E-06	0.77 (0.65 - 0.87)	0.46 (0.21 - 0.67)	0.25 (0.13 - 0.32)	0.96 (0.94 - 0.97)
ESM-1	4.84 (2.35 - 10.69)	5.99E-06	0.76 (0.66 - 0.84)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.27)	0.95 (0.93 - 0.96)
EPHA2	5.15 (2.56 - 10.97)	6.31E-06	0.73 (0.63 - 0.82)	0.29 (0.12 - 0.46)	0.17 (0.08 - 0.25)	0.95 (0.93 - 0.96)
RET	0.18 (0.08 - 0.38)	7.01E-06	0.78 (0.68 - 0.87)	0.42 (0.21 - 0.62)	0.23 (0.13 - 0.31)	0.96 (0.94 - 0.97)
TGFA	0.33 (0.18 - 0.55)	9.61E-06	0.79 (0.69 - 0.87)	0.33 (0.17 - 0.62)	0.19 (0.11 - 0.31)	0.95 (0.94 - 0.97)
MUC16	2.39 (1.63 - 3.65)	1.02E-05	0.72 (0.59 - 0.83)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
ITGAV	0.05 (0.01 - 0.19)	1.29E-05	0.78 (0.68 - 0.87)	0.46 (0.17 - 0.67)	0.25 (0.11 - 0.32)	0.96 (0.94 - 0.97)
EGF	0.55 (0.41 - 0.72)	3.77E-05	0.79 (0.71 - 0.87)	0.5 (0.21 - 0.71)	0.26 (0.13 - 0.34)	0.96 (0.94 - 0.98)
ICOSLG	0.04 (0.01 - 0.20)	5.60E-05	0.77 (0.66 - 0.85)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
CEACAM5	2.05 (1.46 - 2.94)	6.15E-05	0.72 (0.61 - 0.83)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CTSV	0.27 (0.13 - 0.54)	0.00019	0.73 (0.61 - 0.84)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TFPI2	2.91 (1.65 - 5.38)	0.00024	0.7 (0.58 - 0.8)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
WIF1	0.17 (0.06 - 0.45)	0.00031	0.72 (0.61 - 0.82)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
TXLNA	2.21 (1.41 - 3.51)	0.00065	0.69 (0.55 - 0.81)	0.42 (0.17 - 0.62)	0.23 (0.11 - 0.31)	0.96 (0.94 - 0.97)
LYPD3	0.24 (0.10 - 0.57)	0.0012	0.68 (0.57 - 0.79)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CA9	2.21 (1.33 - 3.68)	0.0022	0.65 (0.52 - 0.77)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FCRLB	2.24 (1.32 - 3.74)	0.0033	0.66 (0.53 - 0.78)	0.38 (0.17 - 0.58)	0.21 (0.11 - 0.3)	0.95 (0.94 - 0.97)
TCL1A	0.54 (0.35 - 0.82)	0.0033	0.68 (0.57 - 0.78)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
MDK	2.42 (1.34 - 4.42)	0.0039	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CDKN1A	1.82 (1.19 - 2.75)	0.0066	0.63 (0.48 - 0.76)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FURIN	0.25 (0.09 - 0.70)	0.0083	0.67 (0.54 - 0.79)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TNFSF13	4.17 (1.43 - 12.15)	0.0093	0.64 (0.54 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GAL	0.16 (0.04 - 0.65)	0.011	0.63 (0.51 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFSF10	0.24 (0.08 - 0.72)	0.011	0.67 (0.55 - 0.77)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
CPE	0.31 (0.12 - 0.77)	0.012	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
WFDC2	3.02 (1.27 - 7.34)	0.012	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
PPY	0.74 (0.59 - 0.94)	0.014	0.67 (0.56 - 0.78)	0.21 (0.04 - 0.46)	0.13 (0.03 - 0.25)	0.94 (0.93 - 0.96)

METAP2	1.76 (1.12 - 2.77)	0.015	0.6 (0.44 - 0.74)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
XPNPEP2	0.70 (0.50 - 0.93)	0.018	0.6 (0.49 - 0.7)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
NECTIN4	2.71 (1.19 - 6.04)	0.018	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
Creatinine	0.29 (0.10 - 0.86)	0.024	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.18 (0.07 - 0.27)	0.93 (0.92 - 0.95)
KLK8	0.34 (0.13 - 0.88)	0.026	0.61 (0.47 - 0.74)	0.35 (0.08 - 0.54)	0.2 (0.06 - 0.28)	0.95 (0.93 - 0.96)
CD207	0.35 (0.13 - 0.89)	0.028	0.62 (0.51 - 0.72)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
MIA	0.24 (0.07 - 0.92)	0.038	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
GPNUMB	9.28 (1.10 - 84.13)	0.040	0.63 (0.52 - 0.74)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ERBB2	3.21 (1.06 - 9.50)	0.040	0.56 (0.41 - 0.71)	0.33 (0.17 - 0.54)	0.19 (0.11 - 0.28)	0.95 (0.94 - 0.96)
DLL1	3.06 (1.05 - 9.11)	0.041	0.58 (0.45 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFRSF19	0.45 (0.20 - 0.98)	0.044	0.65 (0.51 - 0.77)	0.33 (0.08 - 0.54)	0.19 (0.06 - 0.28)	0.95 (0.93 - 0.96)
AR	1.47 (1.00 - 2.09)	0.053	0.63 (0.51 - 0.74)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
NT5E	1.76 (0.99 - 3.08)	0.053	0.63 (0.51 - 0.74)	0.17 (0.04 - 0.46)	0.11 (0.03 - 0.25)	0.94 (0.93 - 0.96)
THBS2	1.60 (0.98 - 2.69)	0.060	0.62 (0.48 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
ADAM8	0.42 (0.16 - 1.04)	0.060	0.6 (0.48 - 0.73)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GZMB	0.57 (0.30 - 1.06)	0.077	0.61 (0.48 - 0.74)	0.25 (0.08 - 0.5)	0.15 (0.06 - 0.26)	0.94 (0.93 - 0.96)
IGF1R	0.37 (0.12 - 1.12)	0.078	0.64 (0.52 - 0.77)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
PKM	1.12 (0.98 - 1.30)	0.10	0.57 (0.43 - 0.72)	0.12 (0 - 0.46)	0.1 (0 - 0.29)	0.92 (0.91 - 0.95)
KLK14	0.53 (0.25 - 1.16)	0.11	0.59 (0.48 - 0.7)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
ERBB3	0.32 (0.08 - 1.32)	0.11	0.59 (0.46 - 0.72)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
CRNN	0.67 (0.40 - 1.12)	0.13	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
FOLR3	0.85 (0.64 - 1.05)	0.14	0.57 (0.47 - 0.68)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CXCL13	0.59 (0.28 - 1.18)	0.14	0.58 (0.43 - 0.71)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.962)
SEZ6L	0.39 (0.12 - 1.39)	0.15	0.63 (0.5 - 0.75)	0.29 (0.04 - 0.46)	0.17 (0.03 - 0.25)	0.95 (0.93 - 0.96)
KLK13	0.67 (0.38 - 1.17)	0.16	0.58 (0.45 - 0.72)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
S100A11	0.57 (0.23 - 1.24)	0.16	0.54 (0.42 - 0.66)	0.21 (0.08 - 0.38)	0.13 (0.06 - 0.21)	0.94 (0.93 - 0.95)
ITGB5	2.09 (0.72 - 6.18)	0.18	0.46 (0.33 - 0.59)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.94)
IL6	1.18 (0.91 - 1.46)	0.18	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
MICA/B	1.24 (0.91 - 1.88)	0.19	0.62 (0.49 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CXCL17	1.40 (0.84 - 2.30)	0.19	0.55 (0.46 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CD70	0.62 (0.30 - 1.27)	0.20	0.58 (0.46 - 0.69)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CD160	0.63 (0.30 - 1.28)	0.20	0.57 (0.43 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TLR3	0.70 (0.41 - 1.22)	0.20	0.59 (0.44 - 0.72)	0.17 (0 - 0.38)	0.11 (0 - 0.21)	0.94 (0.93 - 0.95)
VIM	0.81 (0.55 - 1.17)	0.27	0.55 (0.44 - 0.66)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
IFNGR1	1.99 (0.53 - 6.82)	0.30	0.53 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
FGFBP1	1.70 (0.59 - 4.53)	0.32	0.54 (0.39 - 0.68)	0.21 (0.08 - 0.46)	0.13 (0.06 - 0.25)	0.94 (0.93 - 0.96)
LY9	0.64 (0.24 - 1.70)	0.36	0.56 (0.43 - 0.69)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
FOLR1	0.68 (0.28 - 1.65)	0.39	0.59 (0.46 - 0.7)	0.04 (0 - 0.33)	0.03 (0 - 0.19)	0.93 (0.93 - 0.95)
MSLN	1.25 (0.74 - 2.05)	0.40	0.58 (0.49 - 0.66)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
PODXL	2.39 (0.31 - 18.29)	0.40	0.53 (0.4 - 0.67)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
GZMH	1.23 (0.74 - 1.95)	0.41	0.47 (0.34 - 0.6)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
S100A4	0.81 (0.46 - 1.34)	0.42	0.57 (0.42 - 0.7)	0.33 (0.17 - 0.5)	0.19 (0.11 - 0.27)	0.95 (0.94 - 0.96)
ERBB4	0.64 (0.20 - 2.08)	0.45	0.57 (0.43 - 0.69)	0.12 (0 - 0.38)	0.08 (0 - 0.21)	0.93 (0.93 - 0.95)

TGFBR2	0.71 (0.28 - 1.75)	0.46	0.59 (0.45 - 0.71)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
SMAD5	0.57 (0.15 - 2.95)	0.46	0.61 (0.52 - 0.71)	0.04 (0 - 0.12)	0.03 (0 - 0.08)	0.93 (0.93 - 0.94)
VEGFA	0.78 (0.38 - 1.57)	0.49	0.52 (0.39 - 0.65)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
CD48	0.66 (0.19 - 2.29)	0.50	0.53 (0.4 - 0.66)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
RSPO3	1.16 (0.67 - 1.86)	0.57	0.49 (0.38 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN4	0.82 (0.38 - 1.64)	0.59	0.55 (0.42 - 0.68)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
IL6ST	0.87 (0.60 - 2.13)	0.59	0.66 (0.52 - 0.8)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
LYN	1.22 (0.39 - 2.70)	0.69	0.53 (0.38 - 0.67)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
SCAMP3	0.94 (0.68 - 1.26)	0.70	0.5 (0.38 - 0.62)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN1	1.11 (0.62 - 2.02)	0.72	0.52 (0.4 - 0.63)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
SPARC	0.61 (0.05 - 9.54)	0.72	0.48 (0.37 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
TNFRSF4	1.13 (0.55 - 2.19)	0.73	0.5 (0.37 - 0.64)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ABL1	0.92 (0.55 - 1.46)	0.75	0.48 (0.34 - 0.6)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CEACAM1	0.83 (0.34 - 4.06)	0.75	0.54 (0.42 - 0.65)	0.17 (0 - 0.29)	0.11 (0 - 0.17)	0.94 (0.93 - 0.95)
FADD	1.07 (0.65 - 1.64)	0.79	0.55 (0.42 - 0.66)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ADAMTS15	1.09 (0.58 - 2.06)	0.79	0.51 (0.39 - 0.64)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.943)
CD27	1.09 (0.45 - 2.58)	0.84	0.52 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
HGF	1.05 (0.47 - 2.22)	0.91	0.55 (0.41 - 0.7)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
KLK11	0.96 (0.40 - 2.23)	0.92	0.49 (0.39 - 0.61)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ANXA1	0.98 (0.63 - 1.51)	0.94	0.51 (0.39 - 0.63)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
FLT4	0.95 (0.18 - 5.70)	0.96	0.52 (0.4 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
GPC1	1.00 (0.37 - 2.75)	1.00	0.54 (0.41 - 0.67)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)

1116
 1117
 1118
 1119
 1120
 1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135

Supplementary Table 4 ROC AUC, sensitivity (Sens), positive predictive value (PPV) and negative predictive value (NPV) in the validation set of the univariate logistic regression model derived in the discovery set. Markers are ranked according to their respective p values in the discovery set (see Supplementary Table 3). Spec: specificity.

Marker	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	0.80 (0.66 - 0.93)	0.65 (0.48 - 0.87)	0.49 (0.41 - 0.56)	0.95 (0.92 - 0.98)
KITLG	0.82 (0.72 - 0.90)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
CRP	0.85 (0.76 - 0.92)	0.59 (0.32 - 0.86)	0.47 (0.32 - 0.56)	0.94 (0.90 - 0.98)
VWF	0.74 (0.64 - 0.84)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
SDC1	0.72 (0.59 - 0.83)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
KDR	0.77 (0.67 - 0.86)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
TBIL	0.67 (0.55 - 0.77)	0.23 (0.09 - 0.41)	0.25 (0.12 - 0.38)	0.89 (0.87 - 0.91)
TNFRSF6B	0.72 (0.60 - 0.83)	0.39 (0.13 - 0.61)	0.36 (0.16 - 0.47)	0.91 (0.88 - 0.94)
FASLG	0.74 (0.64 - 0.84)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
ESM1	0.73 (0.62 - 0.82)	0.30 (0.13 - 0.52)	0.31 (0.16 - 0.43)	0.90 (0.88 - 0.93)
EPHA2	0.70 (0.56 - 0.82)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
RET	0.69 (0.59 - 0.78)	0.26 (0.09 - 0.43)	0.27 (0.11 - 0.39)	0.89 (0.87 - 0.92)
TGFA	0.71 (0.59 - 0.81)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
MUC16	0.71 (0.58 - 0.84)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
ITGAV	0.77 (0.67 - 0.85)	0.39 (0.13 - 0.57)	0.36 (0.16 - 0.45)	0.91 (0.88 - 0.94)
EGF	0.74 (0.61 - 0.85)	0.52 (0.13 - 0.70)	0.43 (0.16 - 0.50)	0.93 (0.88 - 0.95)

ICOSLG	0.69 (0.59 - 0.79)	0.30 (0.09 - 0.48)	0.31 (0.11 - 0.41)	0.90 (0.87 - 0.92)
CEACAM5	0.72 (0.60 - 0.83)	0.35 (0.13 - 0.52)	0.33 (0.16 - 0.43)	0.91 (0.88 - 0.93)
CTSV	0.74 (0.63 - 0.84)	0.26 (0.09 - 0.57)	0.27 (0.11 - 0.45)	0.89 (0.87 - 0.94)
TFPI2	0.67 (0.54 - 0.78)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
WIF1	0.63 (0.51 - 0.74)	0.17 (0.00 - 0.39)	0.20 (0.00 - 0.36)	0.88 (0.86 - 0.91)
TXLNA	0.64 (0.51 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LYPD3	0.67 (0.54 - 0.79)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
CA9	0.73 (0.64 - 0.82)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FCRLB	0.69 (0.59 - 0.79)	0.26 (0.04 - 0.43)	0.27 (0.06 - 0.39)	0.89 (0.87 - 0.92)
TCL1A	0.58 (0.45 - 0.70)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
MDK	0.70 (0.59 - 0.81)	0.35 (0.17 - 0.57)	0.33 (0.20 - 0.45)	0.91 (0.88 - 0.94)
CDKN1A	0.62 (0.49 - 0.74)	0.13 (0.00 - 0.43)	0.16 (0.00 - 0.39)	0.88 (0.86 - 0.92)
FURIN	0.64 (0.51 - 0.77)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
TNFSF13	0.64 (0.52 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
GAL	0.61 (0.47 - 0.72)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
TNFSF10	0.66 (0.54 - 0.77)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
CPE	0.64 (0.50 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
WFDC2	0.75 (0.62 - 0.86)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
PPY	0.62 (0.51 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
METAP2	0.62 (0.47 - 0.75)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
XPNPEP2	0.57 (0.45 - 0.69)	0.09 (0.00 - 0.30)	0.11 (0.00 - 0.31)	0.87 (0.86 - 0.90)
NECTIN4	0.62 (0.49 - 0.75)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
Creatinine	0.44 (0.29 - 0.58)	0.09 (0.00 - 0.27)	0.12 (0.00 - 0.29)	0.87 (0.86 - 0.89)
KLK8	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
CD207	0.51 (0.38 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
MIA	0.51 (0.40 - 0.63)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
GNMB	0.70 (0.58 - 0.81)	0.30 (0.09 - 0.52)	0.31 (0.11 - 0.43)	0.90 (0.87 - 0.93)
ERBB2	0.47 (0.34 - 0.61)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
DLL1	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
TNFRSF19	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
AR	0.70 (0.57 - 0.81)	0.22 (0.04 - 0.52)	0.24 (0.06 - 0.43)	0.89 (0.87 - 0.93)
NT5E	0.68 (0.55 - 0.80)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
THBS2	0.73 (0.61 - 0.84)	0.43 (0.22 - 0.65)	0.39 (0.24 - 0.49)	0.92 (0.89 - 0.95)
ADAM8	0.50 (0.38 - 0.62)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMB	0.60 (0.47 - 0.73)	0.22 (0.09 - 0.39)	0.24 (0.11 - 0.36)	0.89 (0.87 - 0.91)
IGF1R	0.51 (0.38 - 0.64)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
PKM	0.61 (0.46 - 0.75)	0.23 (0.05 - 0.45)	0.25 (0.06 - 0.40)	0.89 (0.86 - 0.92)
KLK14	0.51 (0.37 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
ERBB3	0.61 (0.50 - 0.72)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
CRNN	0.68 (0.57 - 0.78)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FOLR3	0.54 (0.44 - 0.65)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
CXCL13	0.44 (0.31 - 0.58)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
SEZ6L	0.61 (0.48 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)

KLK13	0.63 (0.51 - 0.74)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
S100A11	0.58 (0.45 - 0.70)	0.17 (0.00 - 0.35)	0.20 (0.00 - 0.33)	0.88 (0.86 - 0.91)
ITGB5	0.50 (0.36 - 0.62)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
IL6	0.69 (0.58 - 0.80)	0.13 (0.00 - 0.39)	0.16 (0.00 - 0.36)	0.88 (0.86 - 0.91)
MICA/B	0.58 (0.45 - 0.69)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
CXCL17	0.52 (0.41 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
CD70	0.49 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD160	0.51 (0.36 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TLR3	0.68 (0.54 - 0.80)	0.43 (0.17 - 0.65)	0.39 (0.20 - 0.49)	0.92 (0.88 - 0.95)
VIM	0.49 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
IFNGR1	0.54 (0.40 - 0.69)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
FGFBP1	0.62 (0.49 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LY9	0.49 (0.36 - 0.62)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
FOLR1	0.51 (0.37 - 0.63)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
MSLN	0.67 (0.56 - 0.79)	0.35 (0.00 - 0.52)	0.33 (0.00 - 0.43)	0.91 (0.86 - 0.93)
PODXL	0.47 (0.34 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMH	0.47 (0.33 - 0.60)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
S100A4	0.54 (0.41 - 0.66)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
ERBB4	0.48 (0.34 - 0.60)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
TGFBR2	0.49 (0.36 - 0.63)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
SMAD5	0.62 (0.51 - 0.73)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
VEGFA	0.53 (0.40 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD48	0.51 (0.39 - 0.64)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
RSPO3	0.48 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CCN4	0.62 (0.49 - 0.74)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
IL6ST	0.68 (0.52 - 0.81)	0.39 (0.22 - 0.61)	0.36 (0.24 - 0.47)	0.91 (0.89 - 0.94)
LYN	0.52 (0.39 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
SCAMP3	0.49 (0.38 - 0.61)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
CCN1	0.50 (0.40 - 0.60)	0.00 (0.00 - 0.04)	0.00 (0.00 - 0.06)	0.86 (0.86 - 0.87)
SPARC	0.52 (0.40 - 0.64)	0.04 (0.00 - 0.26)	0.06 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TNFRSF4	0.64 (0.51 - 0.76)	0.26 (0.00 - 0.48)	0.27 (0.00 - 0.41)	0.89 (0.86 - 0.92)
ABL1	0.51 (0.39 - 0.63)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
CEACAM1	0.54 (0.41 - 0.66)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FADD	0.55 (0.44 - 0.66)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
ADAMTS15	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
CD27	0.61 (0.47 - 0.74)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
HGF	0.51 (0.38 - 0.64)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
KLK11	0.59 (0.46 - 0.70)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
ANXA1	0.50 (0.37 - 0.62)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
FLT4	0.50 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
GPC1	0.57 (0.42 - 0.71)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)

1136

1137

1138

1139 **Supplementary Table 5 Stack logistic regression model coefficient estimates and respective**
 1140 **95% confidence interval (CI) limits and p values.** See statistical analysis sub-section in Methods for
 1141 the detailed description of the stacking procedure. This model was developed in the discovery set.

1142

	Coefficient Estimate	CI 2.5%	CI 97.5%	p value
Intercept	-1.47	-2.34	-0.73	0.00033
Diagnosis				
Healthy	2.50	1.75	3.45	5.41×10 ⁻⁹
Chronic Pancreatitis	2.30	1.57	3.20	2.26×10 ⁻⁸
IgG4 Disease	2.08	1.26	3.07	4.98×10 ⁻⁶
Irritable Bowel Syndrome	1.92	1.08	2.86	1.61×10 ⁻⁵
Other Biliary Duct Disease	2.29	1.15	3.56	0.00016
Sphincter of Oddi Dysfunction	1.64	0.73	2.65	0.00063
No Relevant Diagnosis	-1.73	-3.23	-0.39	0.015
Other Cancer	0.77	0.076	1.51	0.032
Pancreatic Cyst	-1.52	-3.02	-0.17	0.035
Gastritis/Reflux Disease	0.53	-0.44	1.53	0.28
Familial Pancreatic Cancer	0.49	-0.41	1.41	0.29
Acute Pancreatitis	0.34	-0.29	1.027	0.31
Liver Disease	0.38	-0.35	1.14	0.31
Isolated LFTs Derangement	-0.63	-2.03	0.60	0.34
Non-Specific Abdominal Pain	0.301	-0.47	1.05	0.43
Gallstone Disease	0.18	-0.67	1.07	0.68

1143

1144

1145

1146

1147

1148

1149

1150

1151 **Supplementary Table 6 Discovery set data and univariate association with PDAC status.** Odds ratios (OR),
 1152 95% confidence intervals (CI) and p values were calculated according to a logistic regression model with a bias
 1153 reduction method (see statistical section in Methods).

1154

Variable	Cases	Controls	OR	p value
Number of samples	24	333	-	-
Mean age at sample draw (yr) (range)	70.79 (43.00-91.00)	58.39(19.00-89.00)	1.07 (1.03 - 1.11)	4.68e-05
Mean BMI (kg/m2) (range)	25.46 (19.81-41.35)	25.41 (15.22-42.19)	1.01 (0.89-1.12)	0.87
Gender				
Male	18	121	4.98 (2.08 – 13.50)	0.00023
Female	6	212		
Diabetes				
yes	5	52	1.51 (0.51 – 3.84)	0.43
no	281	19		
Ethnicity				
Caucasian	11	189	1.17 (0.70 – 2.02)	0.56
Unknown	9	99		
Asian	3	15		
Other	1	13		
Afro/Caribbean	0	17		

1155

1156
 1157
 1158
 1159
 1160
 1161
 1162
 1163
 1164
 1165
 1166
 1167

Supplementary Table 7 Validation set data and univariate association with PDAC status. Odds ratios (OR), 95% confidence intervals (CI) and p values were calculated according to a logistic regression model with a bias reduction method (see statistical section in Methods).

Variable	Cases	Controls	OR	p value
Number of Samples	23	159	-	-
Mean age at sample draw (yr) (range)	68.61 (53.00 - 83.00)	57.94 (21.00 - 93.00)	1.06 (1.02 - 1.04)	0.00071
Mean BMI (kg/m ²) (range)	24.18 (12.04 - 31.62)	25.64 (17.60 - 38.30)	0.90 (0.78-1.01)	0.080
Gender				
Male	14	58	2.65 (1.11 – 6.58)	0.028
Female	9	101		
Diabetes				
yes	5	52	1.57 (0.51 – 4.23)	0.41
no	281	19		
Ethnicity				
Caucasian	10	102	2.66 (1.42 – 5.17)	0.0020
Unknown	12	32		
Asian	3	15		
Other	1	5		
Afro/Caribbean	0	5		

1168

1169

1170

1171

1172

1173

1174 **Supplementary Table 8 Type and number of subjects with other cancers in the ADEPTS cohort.**

1175 See also Figure 1.

1176

Other Cancer	Number of subjects
Possible gallbladder cancer	1
Low grade dysplasia on ampulla of Vater (Incidental finding)	1
Hilar cholangiocarcinoma, treated Nov 2017	1
Low anal moderately differentiated adenocarcinoma	1
Cholangiocarcinoma, primary sclerosing cholangitis	1
PNET (insulinoma)	1
Bowel cancer in 2011	1
Prostate cancer	1

1177

1178

1179
 1180
 1181
 1182
 1183
 1184
 1185
 1186
 1187
 1188
 1189
 1190

1191 **Supplementary Table 9 Values corresponding to Figure 4.** Only ADEPTS samples were considered
 1192 for this association study. Given that symptoms were not considered in the training of the classifiers,
 1193 we concatenate ADEPTS samples in the discovery and validation sets to verify the associations of
 1194 symptoms and PDAC. A univariate logistic regression model with bias correction was used for each
 1195 symptom to test the association with PDAC.

1196

Symptoms	Number of subjects				OR (95% CI)	p value
	Yes		No			
	Control	Case	Control	Case		
Jaundice	18	22	401	23	20.78 (9.98 - 44.35)	3.22×10 ⁻¹⁵
Weight Loss	39	17	380	28	5.91 (2.96 - 11.62)	1.44×10 ⁻⁰⁶
Asymptomatic	96	3	323	42	0.28 (0.07- 0.74)	0.0077
Reflux	38	0	381	45	0.11 (0.00 - 0.79)	0.022
Bloating	31	0	388	45	0.14 (0.00 - 0.99)	0.048
Dyspepsia	30	0	389	45	0.14 (0.00 - 1.03)	0.054
Abdominal Pain	198	16	221	29	0.62 (0.33 - 1.16)	0.14
Nausea	20	0	399	45	0.21 (0.00 - 1.60)	0.17
Vomiting	19	4	400	41	2.23 (0.67 - 6.03)	0.17
Asymptomatic LFT Derangement	52	8	367	37	1.59 (0.67 - 3.39)	0.28
Anaemia	24	1	395	44	0.54 (0.06 - 2.18)	0.44
Back Pain	1	0	418	45	3.07 (0.02 - 58.34)	0.54
Heartburn	9	0	410	45	0.47 (0.00 - 3.85)	0.57
Change In Bowel Habit	58	7	361	38	1.20 (0.49 - 2.62)	0.67
Rectal Bleeding	10	1	409	44	1.31 (0.14 - 5.80)	0.76
Dysphagia	16	1	403	44	0.82 (0.09 - 3.42)	0.82

1197
 1198
 1199
 1200
 1201
 1202
 1203
 1204
 1205
 1206

1207 **Supplementary Table 10 Performance model rank summary for selected models in symptomatic patients.**
 1208 The probability values used to calculate the performance metrics were generated with each model developed in
 1209 the training set and reported in the main text. Probability values for symptomatic patients belonging to the training
 1210 set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms
 1211 information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel
 1212 Habit. W. Loss: Weight Loss. Here, only the ranks of the performances are provided. For the respective
 1213 performance values see Table 2 in the main text.

1214

Models	Metric	Symptom (Yes)					Geometric mean rank	Mean across all metrics
		A.L.Derang.	A.Pain	A.B. Habit	W. Loss	Jaundice		
CA19-9	ROC	3	3	3	3	3	3.00	2.83
	Sens90	3	3	2	3	3	2.77	
	PPV90	3	3	2	3	3	2.77	
	NPV90	3	3	2	3	3	2.77	
Index signature	ROC	1	1	1	1	1	1.00	1.16
	Sens90	2	1	1	1	2	1.32	
	PPV90	2	1	1	1	1	1.15	
	NPV90	1	1	1	1	2	1.15	
Reduced signature	ROC	2	2	2	2	2	2.00	1.79
	Sens90	1	2	3	2	1	1.64	
	PPV90	1	2	3	2	2	1.89	
	NPV90	1	2	3	2	1	1.64	

1215
 1216
 1217
 1218
 1219
 1220
 1221
 1222

1223 **Supplementary Table 11 Pairwise area under receiver operating characteristic curve comparison p-values**
 1224 **for the selected models in Table 2 (main text).** Only ADEPTS samples had symptoms information. A. L. Derang.:
 1225 Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss.
 1226 For the respective performance values see Table 2 in the main text. Models in rows for each symptom are
 1227 compared with those in the columns for the same symptom. 10000 bootstraps were constructed to test the
 1228 significance of the difference in performance being lower.
 1229

Symptom (Yes)		Reduced signature	Index signature
A.L.Derang.	CA19-9	3.89×10^{-07}	7.70×10^{-26}
	Reduced signature	-	0.25
A. Pain	CA19-9	2.19×10^{-15}	2.83×10^{-93}
	Reduced signature	-	1.08×10^{-06}
A. B. Habit	CA19-9	0.0018	1.48×10^{-28}
	Reduced signature	-	0.020
W.Loss	CA19-9	2.04×10^{-09}	1.38×10^{-14}
	Reduced signature	-	0.018
Jaundice	CA19-9	0.013	3.34×10^{-07}
	Reduced signature	-	0.069

1230

1231

1232

1233

1234

1235

1236

1237 **References**

1238

- 1239 1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. *The Lancet*. 2016;388:73-
 1240 85.
- 1241 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
 1242 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
 1243 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021;71:209-49.
- 1244 3. Carioli G, Malvezzi M, Bertuccio P, Boffetta P, Levi F, Vecchia CL, et al. European
 1245 cancer mortality predictions for the year 2021 with focus on pancreatic and female lung
 1246 cancer. *Annals of Oncology*. 2021;32:478-87.
- 1247 4. Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, et al. European
 1248 cancer mortality predictions for the year 2022 with focus on ovarian cancer. *Ann Oncol*.
 1249 2022;33(3):330-9.
- 1250 5. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM.
 1251 Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver,
 1252 and Pancreas Cancers in the United States. *Cancer Research*. 2014;74:2913-21.
- 1253 6. Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, Risk
 1254 Factors for, and Trends in Pancreatic Cancer. *Gastroenterology*. 2021;160:744-54.

- 1255 7. Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M,
1256 et al. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a
1257 Predictor of Outcome Beyond the TNM. *Annals of Surgery*. 2017;266(1).
- 1258 8. Zerboni G, Signoretti M, Crippa S, Falconi M, Arcidiacono PG, Capurso G. Systematic
1259 review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in
1260 asymptomatic individuals. *Pancreatology*. 2019;19:2-9.
- 1261 9. Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, et al. Early detection of
1262 pancreatic cancer. *The Lancet Gastroenterology and Hepatology*. 2020.
- 1263 10. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer
1264 Screening in High-Risk Individuals: Expert Review. *Gastroenterology*. 2020;159:358-62.
- 1265 11. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening
1266 for Pancreatic Cancer. *JAMA*. 2019;322:438-.
- 1267 12. Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, et al.
1268 Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A
1269 Systematic Review and Meta-Analysis. *Gastroenterology*. 2022;162:786-98.
- 1270 13. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut*.
1271 2018;67:789-804.
- 1272 14. Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, et al. Symptoms and
1273 patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM
1274 pancreatic study): a prospective cohort study. *The Lancet Gastroenterology & Hepatology*.
1275 2016;1:298-306.
- 1276 15. Lukacs G, Kovacs A, Csanadi M, Moizis M, Repa I, Kalo Z, et al. Benefits Of Timely Care
1277 In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence.
1278 *Cancer Manag Res*. 2019;11:9849-61.
- 1279 16. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of
1280 pancreatic ductal adenocarcinoma from low-to-high tumour stages. *Gut*. 2015;64(11):1783-
1281 9.
- 1282 17. Ahn SJ, Choi SJ, Kim HS. Time to Progression of Pancreatic Cancer: Evaluation with
1283 Multi-Detector Computed Tomography. *J Gastrointest Cancer*. 2017;48(2):164-9.
- 1284 18. Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how
1285 difficult is the diagnosis? *BMJ*. 2014;349:g7400.
- 1286 19. Escorza-Calzada S, Rosas-Camargo V, Melchor-Ruan J, Meneses-Medina M, Cedro-
1287 Tanda A, Huitzil-Melendez F. P-319 Delay in pancreatic cancer diagnosis and treatment: Call
1288 to action. *Annals of Oncology*. 2023;34:S127.
- 1289 20. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the
1290 incidence of early symptoms in pancreatic and biliary tract cancer. *BMJ open*.
1291 2014;4:e005720-e.
- 1292 21. Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, et al.
1293 Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine
1294 neoplasms: a nested case-control study of the UK primary care population. *British Journal of*
1295 *General Practice*. 2021;71:e836-e45.
- 1296 22. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in
1297 Primary Care. *Pancreas*. 2016;45:814-8.
- 1298 23. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. *The Lancet*.
1299 2020;395:2008-20.
- 1300 24. [Available from: <https://www.nice.org.uk>].

- 1301 25. Hippisley-Cox J, Coupland C. Development and validation of risk prediction
1302 algorithms to estimate future risk of common cancers in men and women: prospective
1303 cohort study. *BMJ Open*. 2015;5:e007825-e.
- 1304 26. Hamilton W. The CAPER studies: five case-control studies aimed at identifying and
1305 quantifying the risk of cancer in symptomatic primary care patients. *British Journal of*
1306 *Cancer*. 2009;101:S80-S6.
- 1307 27. Usher-Smith J, Emery J, Hamilton W, Griffin SJ, Walter FM. Risk prediction tools for
1308 cancer in primary care. *British Journal of Cancer*. 2015;113:1645-50.
- 1309 28. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic
1310 and predictive value of serum CA19.9 in pancreatic cancer. *Annals of Oncology*.
1311 2012;23:1713-22.
- 1312 29. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, et al. Roles of CA19-9 in pancreatic
1313 cancer: Biomarker, predictor and promoter. *Biochimica et Biophysica Acta (BBA) - Reviews*
1314 *on Cancer*. 2021;1875(2):188409.
- 1315 30. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the
1316 diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based
1317 appraisal. *J Gastrointest Oncol*. 2012;3(2):105-19.
- 1318 31. Kim Y, Yeo I, Huh I, Kim J, Han D, Jang JY, et al. Development and Multiple Validation
1319 of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer. *Clin Cancer Res*.
1320 2021;27(8):2236-45.
- 1321 32. Potjer TP. Pancreatic cancer surveillance and its ongoing challenges: is it time to
1322 refine our eligibility criteria? *Gut*. 2022;71:1047-9.
- 1323 33. Pereira S, Hippisley-Cox J, Timms J, Hsuan J, Fusai K, Williams N, et al. ADEPTS
1324 (Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS) and EDRA (Early
1325 Diagnosis Research Alliance). *Pancreatology*. 2020;20(8):e14.
- 1326 34. Price S, Spencer A, Medina-Lara A, Hamilton W. Availability and use of cancer
1327 decision-support tools: a cross-sectional survey of UK primary care. *Br J Gen Pract*.
1328 2019;69(684):e437-e43.
- 1329 35. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian
1330 cancer population screening and mortality after long-term follow-up in the UK Collaborative
1331 Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*.
1332 2021;397(10290):2182-93.
- 1333 36. Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Serum
1334 biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble
1335 learning. *Communications Medicine*. 2023;3:10-.
- 1336 37. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity
1337 and specificity of multimodal and ultrasound screening for ovarian cancer, and stage
1338 distribution of detected cancers: results of the prevalence screen of the UK Collaborative
1339 Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol*. 2009;10(4):327-40.
- 1340 38. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al.
1341 Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. *Bmj*.
1342 2008;337:a2079.
- 1343 39. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S,
1344 Fourkala EO, et al. Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis
1345 with pancreatic cancer: implications for early disease detection. *Clin Cancer Res*.
1346 2015;21(3):622-31.

- 1347 40. Data normalization and standardization [Available from:
1348 [https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-](https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-v2.0.pdf)
1349 [v2.0.pdf](https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-v2.0.pdf).
- 1350 41. Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Early
1351 detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on
1352 a panel of protein serum biomarkers. medRxiv. 2021:2021.12.02.21267187.
- 1353 42. Caruana R, Niculescu-Mizil A, Crew G, Ksikes A. Ensemble selection from libraries of
1354 models. Proceedings of the twenty-first international conference on Machine learning;
1355 Banff, Alberta, Canada: Association for Computing Machinery; 2004. p. 18.
- 1356 43. Whalen S, Pandey G, editors. A Comparative Analysis of Ensemble Classifiers: Case
1357 Studies in Genomics. 2013 IEEE 13th International Conference on Data Mining; 2013 7-10
1358 Dec. 2013.
- 1359 44. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of
1360 microarray gene-expression data. Proc Natl Acad Sci U S A. 2002;99(10):6562-6.
- 1361 45. Whalen S, Schreiber J, Noble WS, Pollard KS. Navigating the pitfalls of applying
1362 machine learning in genomics. Nat Rev Genet. 2022;23(3):169-81.
- 1363 46. Teschendorff AE. Avoiding common pitfalls in machine learning omic data science.
1364 Nat Mater. 2019;18(5):422-7.
- 1365 47. Julia H-C, Carol C. Development and validation of risk prediction algorithms to
1366 estimate future risk of common cancers in men and women: prospective cohort study. BMJ
1367 Open. 2015;5(3):e007825.
- 1368 48. Scholbeck CA, Molnar C, Heumann C, Bischl B, Casalicchio G, editors. Sampling,
1369 Intervention, Prediction, Aggregation: A Generalized Framework for Model-Agnostic
1370 Interpretations. Machine Learning and Knowledge Discovery in Databases; 2020 2020//;
1371 Cham: Springer International Publishing.
- 1372 49. James AD, Richardson DA, Oh IW, Sritangos P, Attard T, Barrett L, et al. Cutting off
1373 the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2
1374 (PKM2). Br J Cancer. 2020;122(2):266-78.
- 1375 50. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, et al. MUC4
1376 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J
1377 Cancer. 2008;98(10):1675-81.
- 1378 51. Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, et al.
1379 Identification of a serum biomarker panel for the differential diagnosis of
1380 cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget. 2018;9(25):17430-42.
- 1381 52. Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al.
1382 PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to
1383 Allogeneic Dendritic Cells. Frontiers in Immunology. 2017;8.
- 1384 53. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor
1385 Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell.
1386 2019;178(4):795-806 e12.
- 1387 54. Peng H, James CA, Cullinan DR, Hogg GD, Mudd JL, Zuo C, et al. Neoadjuvant
1388 FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor
1389 Cells in Patients with Pancreatic Cancer. Clinical Cancer Research. 2021;27(24):6761-71.
- 1390 55. Wang C, Li X, Zhang L, Chen Y, Dong R, Zhang J, et al. miR-194-5p down-regulates
1391 tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Int
1392 Immunopharmacol. 2021;97:107822.
- 1393 56. Qcancer®-2018 risk calculator for men: <http://qcancer.org/male> [

1394 57. Qcancer®-2018 risk calculator for women: <http://qcancer.org/female> [
1395 58. Kane LE, Mellotte GS, Mylod E, O'Brien RM, O'Connell F, Buckley CE, et al. Diagnostic
1396 Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-
1397 analysis. *Cancer Res Commun.* 2022;2(10):1229-43.
1398 59. Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal
1399 Adenocarcinoma on Diagnosis, Surveillance and Therapy. *Cancers.* 2022;14:217-
1400 60. Azizian A, Ruhlmann F, Krause T, Bernhardt M, Jo P, König A, et al. CA19-9 for
1401 detecting recurrence of pancreatic cancer. *Sci Rep.* 2020;10(1):1332.
1402 61. Sagi O, Rokach L. Ensemble learning: A survey. *WIREs Data Mining and Knowledge*
1403 *Discovery.* 2018;8(4):e1249.
1404 62. Benjamin JL, Maruan A-S, Amir A, Jennifer W, Sami L, Eric PX. Discriminative
1405 Subtyping of Lung Cancers from Histopathology Images via Contextual Deep Learning.
1406 *medRxiv.* 2022:2020.06.25.20140053.
1407 63. Placido D, Yuan B, Hjaltelin JX, Zheng C, Haue AD, Chmura PJ, et al. A deep learning
1408 algorithm to predict risk of pancreatic cancer from disease trajectories. *Nat Med.*
1409 2023;29(5):1113-22.
1410 64. Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al.
1411 Improved early detection of ovarian cancer using longitudinal multimarker models. *British*
1412 *Journal of Cancer.* 2020;122(6):847-56.
1413
1414